Document:

Form of Indemnification Agreement

 Exhibit 10.3 
 INDEMNIFICATION AGREEMENT 
 This Agreement is made as of
            , 201_, between GigOptix, Inc., a Delaware corporation (the “Company”), and              (the
“Indemnitee”). 
 RECITALS 
 Both the Company and Indemnitee recognize that highly competent persons have become more reluctant to serve publicly-held corporations as directors or in other capacities unless they are provided with
adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation. 

In recognition of Indemnitee’s need for substantial protection against personal liability in order to enhance Indemnitee’s
continued service to the Company in an effective manner and Indemnitee’s reliance on the provisions of the Company’s Certificate of Incorporation (“Certificate of Incorporation”) and the Company’s Bylaws (the
“Bylaws”) requiring indemnification of the Indemnitee to the fullest extent permitted by law, and in part to provide Indemnitee with specific contractual assurance that the protection promised by such Certificate of Incorporation and
Bylaws will be available to Indemnitee (regardless of, among other things, any amendment to or revocation of such Certificate of Incorporation or Bylaws or any change in the composition of the Company’s Board of Directors or acquisition
transaction relating to the Company), the Company wishes to provide in this Agreement for the indemnification of and the advancing of expenses to Indemnitee to the fullest extent (whether partial or complete) permitted by law and as set forth in
this Agreement. 
 The Certificate of Incorporation, the Bylaws and the General Corporation Law of the State of Delaware
(“DGCL”) expressly provide that the indemnification provisions set forth therein are not exclusive and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other
persons with respect to indemnification. 
 It is reasonable, prudent and necessary for the Company contractually to obligate
itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified.

 This Agreement is a supplement to and in furtherance of the Certificate of Incorporation and Bylaws and any resolutions
adopted pursuant thereto and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder. 

 AGREEMENT 

In consideration of the premises and of Indemnitee agreeing to serve or continuing to serve the Company directly or, at its request, with
another enterprise, and intending to be legally bound hereby, the parties hereto agree as follows: 
 1. Basic
Indemnification Agreement. 
 (a) In the event Indemnitee was, is or becomes a party to or
witness or other participant in, or is threatened to be made a party to or witness or other participant in, a Claim (as defined in Section 9(b)) by reason of (or arising in part out of) an Indemnifiable Event (as defined in Section 9(d)),
the Company shall indemnify Indemnitee to the fullest extent permitted by law as soon as practicable but in any event no later than 30 days after written demand is presented to the Company, against any and all Expenses (as defined in
Section 9(c)), judgments, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection therewith) of such Claim actually and reasonably incurred by or on behalf of
Indemnitee in connection with such Claim and any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement. If requested by Indemnitee in writing, the Company shall
advance (within ten business days of such written request) any and all Expenses to Indemnitee (an “Expense Advance”). Notwithstanding anything in this Agreement to the contrary, prior to a Change of Control (as defined in
Section 9(a)) and except as set forth in Sections 1(b), 3 and 7, Indemnitee shall not be entitled to indemnification pursuant to this Agreement in connection with any Claim (i) initiated by Indemnitee against the Company or any director or
officer of the Company unless the Company has joined in or consented to the initiation of such Claim; (ii) made on account of Indemnitee’s conduct which constitutes a breach of Indemnitee’s duty of loyalty to the Company or its
stockholders or is an act or omission not in good faith or which involves intentional misconduct or a knowing violation of the law; or (iii) arising from the purchase and sale by Indemnitee of securities in violation of Section 16(b) of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”). 
 (b) Notwithstanding the
foregoing, (i) the indemnification obligations of the Company under Section 1(a) shall not be applicable if the Reviewing Party (as defined in Section 9(e)) has determined (in a written opinion, in any case in which the special
independent counsel referred to in Section 2 is involved) that Indemnitee would not be permitted to be indemnified under applicable law, and (ii) the obligation of the Company to make an Expense Advance pursuant to Section 1(a) shall
be subject to the condition that the Company receives an undertaking that, if, when and to the extent that the Reviewing Party determines that Indemnitee would not be permitted to be so indemnified under applicable law, the Company shall be entitled
to be reimbursed by Indemnitee (who hereby agrees to reimburse the Company) for all such amounts theretofore paid; provided, however, that if Indemnitee has commenced legal proceedings in the Court of Chancery of the State of Delaware (the
“Delaware Court”) to secure a determination that Indemnitee should be indemnified under applicable law, any determination made by the Reviewing Party that Indemnitee would not be permitted to be indemnified under applicable law shall not
be binding and Indemnitee shall not be required to reimburse the Company for any Expense Advance until a final judicial determination is made with respect thereto (as to which all rights of appeal therefrom have been exhausted or lapsed).
Indemnitee’s 

  
 -2-

 
obligation to reimburse the Company for Expense Advances shall be unsecured and no interest shall be charged thereon. If there has not been a Change in Control, the Reviewing Party shall be
selected by the Board of Directors, and if there has been such a Change in Control, the Reviewing Party shall be the special independent counsel referred to in Section 2. If there has been no determination by the Reviewing Party or if the
Reviewing Party determines that Indemnitee substantively would not be permitted to be indemnified in whole or in part under applicable law, Indemnitee shall have the right to commence litigation in the Delaware Court seeking an initial determination
by the court or challenging any such determination by the Reviewing Party or any aspect thereof and the Company hereby consents to service of process and to appear in any such proceeding. Any determination by the Reviewing Party otherwise shall be
conclusive and binding on the Company and Indemnitee. The Company shall indemnify Indemnitee for Expenses incurred by Indemnitee in connection with the successful establishment or enforcement, in whole or in part, by Indemnitee of Indemnitee’s
right to indemnification or advances. 
 2. Change in Control. The Company agrees that if there is a Change in
Control of the Company (other than a Change in Control which has been approved by two- thirds or more of the Company’s Board of Directors who were directors immediately prior to such Change in Control) then with respect to all matters
thereafter arising concerning the rights of Indemnitee to indemnity payments and Expense Advances under this Agreement or any other agreement, the Bylaws or Certificate of Incorporation now or hereafter in effect relating to Claims for Indemnifiable
Events, the Company shall seek legal advice only from special independent counsel selected by Indemnitee and approved by the Company (which approval shall not be unreasonably withheld or delayed) and who has not otherwise performed services for the
Company within the last five years (other than in connection with such matters) or for Indemnitee. In the event that Indemnitee and the Company are unable to agree on the selection of the special independent counsel, such special independent counsel
shall be selected by lot from among at least five law firms with offices in the State of Delaware having more than fifty attorneys, having a rating of “av” or better in the then current Martindale Hubbell Law Directory and having attorneys
which specialize in corporate law. Such selection shall be made in the presence of Indemnitee (and his legal counsel or either of them, as Indemnitee may elect). Such counsel, among other things, shall, within 90 days of its retention, render its
written opinion to the Company and Indemnitee as to whether and to what extent Indemnitee would be permitted to be indemnified under applicable law. The Company agrees to pay the reasonable fees of the special independent counsel referred to above
and to fully indemnify such counsel against any and all expenses (including attorneys’ fees), claims, liabilities, and damages arising out of or relating to this Agreement or its engagement pursuant hereto. 

3. Indemnification for Additional Expenses. The Company shall indemnify Indemnitee against any and all expenses (including
attorneys’ fees) and, if requested by Indemnitee in writing, shall (within ten business days of such written request) advance such expenses to Indemnitee, which are incurred by Indemnitee in connection with any Claim asserted against or action
brought by Indemnitee for (i) indemnification or advance payment of Expenses by the Company under this Agreement or any other agreement, the Bylaws or Certificate of Incorporation now or hereafter in effect relating to Claims for Indemnifiable
Events and/or (ii) recovery under any directors’ and officers’ liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such

  
 -3-

 
indemnification, advance expense payment or insurance recovery, as the case may be. The Indemnitee shall qualify for advances solely upon the execution and delivery to the Company of an
undertaking providing that the Indemnitee undertakes to repay the advance to the extent that it is ultimately determined that the Indemnitee is not entitled to be indemnified by the Company. 

4. Partial Indemnity. If Indemnitee is entitled under any provisions of this Agreement to indemnification by the Company of
some but not all of the Expenses, liabilities, judgments, fines, penalties and amounts paid in settlement of a Claim, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled. Moreover,
notwithstanding any other provision of this Agreement, to the extent that Indemnitee has been successful on the merits or otherwise in defense of any or all Claims relating in whole or in part to an Indemnifiable Event or in defense of any issue or
matter therein, including dismissal without prejudice, Indemnitee shall be indemnified against all Expenses incurred in connection therewith. In connection with any determination by the Reviewing Party or otherwise as to whether Indemnitee is
entitled to be indemnified hereunder the burden of proof shall be on the Company to establish that Indemnitee is not so entitled. 
 5. No Presumption. For purposes of this Agreement, the termination of any action, suit or proceeding by judgment, order, settlement (whether with or without court approval) or conviction, or
upon a plea of nolo contendere, or its equivalent, shall not create a presumption that Indemnitee did not meet any particular standard of conduct or have any particular belief. 

6. Notification and Defense of Claim. Within 30 days after receipt by Indemnitee of notice of the commencement of a Claim
which may involve an Indemnifiable Event, Indemnitee will, if a claim in respect thereof is to be made against the Company under this Agreement, submit to the Company a written notice identifying the proceeding, but the omission so to notify the
Company will not relieve it from any liability which it may have to Indemnitee under this Agreement unless the Company is materially prejudiced by such lack of notice. With respect to any such Claim as to which Indemnitee notifies the Company of the
commencement thereof: 
 (a) the Company will be entitled to participate therein at its own expense; 

(b) except as otherwise provided below, to the extent that it may wish, the Company jointly with any other indemnifying
party similarly notified will be entitled to assume the defense thereof, with counsel selected by the Board of Directors and satisfactory to Indemnitee. After notice from the Company to Indemnitee of its election to assume the defense thereof, the
Company will not be liable to Indemnitee under this Agreement for any legal or other expenses subsequently incurred by Indemnitee in connection with the defense thereof other than reasonable costs of investigation or as otherwise provided below.
Indemnitee shall have the right to employ its own counsel in such action, suit or proceeding, but the fees and expenses of such counsel incurred after notice from the Company of its assumption of the defense thereof shall be at the expense of
Indemnitee unless (i) the employment of counsel by Indemnitee has been authorized by the Company, (ii) Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and the Indemnitee in the
conduct of the defense of such action, or (iii) the Company shall not in fact have employed counsel to assume the defense of such action, in each of which cases the fees and expenses of counsel shall be at the

  
 -4-

 
expense of the Company. The Company shall not be entitled to assume the defense of any claim brought by or on behalf of the Company or as to which Indemnitee shall have made the conclusion
provided for in clause (ii) above; and 
 (c) the Company shall not be liable to indemnify Indemnitee under
this Agreement for any amounts paid in settlement of any action or claim effected without its written consent. The Company shall not settle any action or claim in any manner which would impose any penalty or limitation on Indemnitee without
Indemnitee’s written consent. Neither the Company nor Indemnitee will unreasonably withhold or delay their consent to any proposed settlement. 
 7. Non-exclusivity. The rights of Indemnitee hereunder shall be in addition to any other rights Indemnitee may have under the Certificate of Incorporation, the Bylaws, the DGCL, any
agreement, a vote of the stockholders, a resolution of directors or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any
action taken or omitted by such Indemnitee acting on behalf of the Company and at the request of the Company prior to such amendment, alteration or repeal. To the extent that a change in the DGCL (whether by statute or judicial decision), the
Certificate of Incorporation or the Bylaws permits greater indemnification by agreement than would be afforded currently under the Certificate of Incorporation, the Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee
shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to
every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any
other right or remedy. 
 8. Liability Insurance. To the extent the Company maintains an insurance policy or
policies providing directors’ and officers’ liability insurance, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any Company director or
officer. If, at the time the Company receives notice from any source of a Claim as to which Indemnitee is a party or a participant (as a witness or otherwise), the Company has director and officer liability insurance in effect, the Company shall
give prompt notice of such Proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the
Indemnitee, all amounts payable as a result of such Claim in accordance with the terms of such policies. The Company shall indemnify Indemnitee for Expenses incurred by Indemnitee in connection with any successful action brought by Indemnitee for
recovery under any insurance policy referred to in this Section 8 and shall advance to Indemnitee the Expenses of such action in the manner provided in Section 3 above. 

  
 -5-

 9. Certain Definitions. 

(a) A “Change in Control” shall be deemed to have occurred if: 

(1) any person, as that term is used in Section 13(d) and Section 14(d)(2) of the Exchange Act, becomes, is
discovered to be, or files a report on Schedule 13D or 14D-1 (or any successor schedule, form or report) disclosing that such person is a beneficial owner (as defined in Rule 13d-3 under the Exchange Act or any successor rule or regulation),
directly or indirectly, of securities of the Company representing 20% or more of the total voting power of the Company’s then outstanding Voting Securities (unless such person becomes such a beneficial owner in connection with the initial
public offering of the Company); 
 (2) during any period of two consecutive years, individuals who at the
beginning of such period constitute the Board of Directors of the Company and any new director whose election by the Board of Directors or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds of
the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; 

(3) the Company, or any material subsidiary of the Company, is merged, consolidated or reorganized into or with another
corporation or other legal person (an “Acquiring Person”) or securities of the Company are exchanged for securities of an Acquiring Person, and immediately after such merger, consolidation, reorganization or exchange less than a majority
of the combined voting power of the then outstanding securities of the Acquiring Person immediately after such transaction are held, directly or indirectly, in the aggregate by the holders of Voting Securities immediately prior to such transaction;

 (4) the Company, or any material subsidiary of the Company, in any transaction or series of related
transactions, sells or otherwise transfers all or substantially all of its assets to an Acquiring Person, and less than a majority of the combined voting power of the then outstanding securities of the Acquiring Person immediately after such sale or
transfer is held, directly or indirectly, in the aggregate by the holders of Voting Securities immediately prior to such sale or transfer; 
 (5) the Company and its subsidiaries, in any transaction or series of related transactions, sells or otherwise transfers business operations that generated two thirds or more of the consolidated revenues
(determined on the basis of the Company’s four most recently completed fiscal quarters) of the Company and its subsidiaries immediately prior thereto; 
 (6) the Company files a report or proxy statement with the Securities and Exchange Commission pursuant to the Exchange Act disclosing that a change

  
 -6-

 
in control of the Company has or may have occurred or will or may occur in the future pursuant to any then existing contract or transaction; or 

(7) any other transaction or series of related transactions occur that have substantially the effect of the transactions
specified in any of the preceding clauses in this paragraph (ii). 
 Notwithstanding the provisions of Section 9(a)(1) or 9(a)(4), unless
otherwise determined in a specific case by majority vote of the Board of Directors of the Company, a Change of Control shall not be deemed to have occurred for purposes of this Agreement solely because (i) the Company, (ii) an entity in
which the Company directly or indirectly beneficially owns 50% or more of the voting securities or (iii) any Company sponsored employee stock ownership plan, or any other employee benefit plan of the Company, either files or becomes obligated
to file a report or a proxy statement under or in response to Schedule 13D, Schedule 14D-1, Form 8-K or Schedule 14A (or any successor schedule, form or report or item therein) under the Exchange Act, disclosing beneficial ownership by it of shares
of stock of the Company, or because the Company reports that a Change in Control of the Company has or may have occurred or will or may occur in the future by reason of such beneficial ownership. 

(b) A “Claim” is any threatened, pending or completed action, suit, proceeding or alternative dispute resolution
mechanism, or any inquiry, hearing or investigation whether conducted by the Company or any other party, whether civil, criminal, administrative, investigative or other. 

(c) “Expenses” include attorneys’ fees and all other costs, fees, expenses and obligations of any nature
whatsoever paid or incurred in connection with investigating, defending, being a witness in or participating in (including appeal), or preparing to defend, be a witness in or participate in any Claim relating to any Indemnifiable Event. 

(d) An “Indemnifiable Event” is any event or occurrence (whether before or after the date hereof) related to the
fact that Indemnitee is or was a director, officer, employee, consultant, agent or fiduciary of or to the Company, or any subsidiary of the Company, or is or was serving at the request of the Company as a director, officer, employee, trustee, agent
or fiduciary of another corporation, partnership, joint venture, employee benefit plan, trust or other enterprise, or by reason of anything done or not done by Indemnitee in any such capacity. 

(e) A “Reviewing Party” is (i) a majority of the Company’s Board of Directors who are not parties to
such Claim for which Indemnitee is seeking indemnification, even though less than a quorum, (ii) by a committee of directors who are not parties to such Claim for which Indemnitee is seeking indemnification that is designated by majority vote
of such directors, even though less than a quorum, or (iii) if there are no directors who are not parties to such Claim for which Indemnitee is seeking indemnification, or if such directors so direct, or if there has been a Change in Control,
the special independent counsel referred to in Section 2 hereof. 
 (f) “Voting Securities” means
any securities of the Company which vote generally in the election of directors. 

  
 -7-

 10. Amendments, Termination and Waiver. No supplement, modification, amendment
or termination of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or
not similar) nor shall such waiver constitute a continuing waiver. 
 11. Contribution. If the indemnification
provided in Sections 1 and 3 is unavailable, then, in respect of any Claim in which the Company is jointly liable with Indemnitee (or would be if joined in the Claim), the Company shall contribute to the amount of Expenses, judgments, fines,
penalties and amounts paid in settlement as appropriate to reflect: (i) the relative benefits received by the Company, on the one hand, and Indemnitee, on the other hand, from the transaction from which the Claim arose, and (ii) the
relative fault of the Company, on the one hand, and of Indemnitee, on the other, in connection with the events which resulted in such Expenses, judgments, fines, penalties and amounts paid in settlement, as well as any other relevant equitable
considerations. The relative fault of the Company, on the one hand, and of Indemnitee, on the other, shall be determined by reference to, among other things, the parties’ relative intent, knowledge, access to information and opportunity to
correct or prevent the circumstances resulting in such Expenses and Liabilities. The Company agrees that it would not be just and equitable if contribution pursuant to this Section 11 were determined by pro rata allocation or any other method
of allocation which does not take account of the equitable considerations described in this Section 11. 
 12.
Subrogation. In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and shall do everything that
may be necessary to secure such rights, including the execution of such documents necessary to enable the Company effectively to bring suit to enforce such rights. 
 13. No Duplication of Payments. The Company shall not be liable under this Agreement to make any payment in connection with any Claim made against Indemnitee to the extent Indemnitee has
otherwise actually received payment (under insurance policy, Certificate of Incorporation or otherwise) of the amounts otherwise identifiable hereunder. 
 14. Entire Agreement. This Agreement contains the final, complete and exclusive statement of the agreement between the Company and Indemnitee with respect to the subject matter of this
Agreement and supersedes any prior or contemporaneous understandings, agreements, communications, correspondence or representations by or between the parties, whether written or oral, relating to the subject matter of this Agreement. 

15. Binding Effect. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties
hereto and their respective successors, assigns, including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business and/or assets of the Company, spouse, heirs, and personal and
legal representatives. This Agreement shall continue in effect regardless of whether Indemnitee continues to serve as a director or officer (or in one of the capacities enumerated in Section 9(d) hereof) of the Company or of any other
enterprise at the Board of Director’s request. 

  
 -8-

 16. Severability. The provisions of this Agreement shall be severable in the
event that any of the provisions hereof (including any provision within a single section, paragraph or sentence) are held by a court of competent jurisdiction to be invalid, void or otherwise unenforceable, and the remaining provisions shall remain
enforceable to the fullest extent permitted by law. 
 17. Applicable Law and Consent to Jurisdiction. This
Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. The Company and Indemnitee hereby irrevocably
and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court and not in any other state or federal court in the United States of America or any court
in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint, irrevocably, to the extent such
party is not a resident of the State of Delaware, as its agent in the State of Delaware as such party’s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and
validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v) waive, and agree not to plead or to make, any
claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum. 

18. Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all
purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this
Agreement. 
 Executed this             day of
            , 201_. 
  

			
	GigOptix, Inc.
		
	By:	 	 
		 	[Name]
		 	[Title]
		
		 	 
		 	[Indemnitee]

  
 -9-Amended and Restated Investor Rights Agreement

 Exhibit 4.7 
 TRIUS THERAPEUTICS, INC. 
 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 THIS AMENDED AND RESTATED
INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of March 19, 2008, by and among TRIUS THERAPEUTICS, INC., a
Delaware corporation (the “Company”) and the investors listed on Exhibit A hereto (referred to hereinafter as the “Investors” and each individually as an “Investor”).

 RECITALS 
 WHEREAS, in connection with the Company’s prior sale of its Series A-2 Preferred Stock (the “Series A-2 Stock”), the Company and certain of the
Investors entered into that certain Amended and Restated Investor Rights Agreement dated February 13, 2007 (the “Prior Agreement”); 
 WHEREAS, the Company proposes to enter into a financing involving, among other things, the purchase by certain of the Investors of shares of the Company’s Series
B Preferred Stock (the “Series B Stock”) pursuant to that certain Series B Preferred Stock Purchase Agreement (the “Purchase Agreement”) of even date herewith (the “Financing”);
and 
 WHEREAS, as a condition to entering into the Purchase
Agreement and in connection with the consummation of the Financing, the Investors have requested the Company extend to them registration rights, information rights and other rights as set forth below, and to terminate the Prior Agreement and to
accept, as applicable, rights and covenants hereunder in lieu of their rights and covenants under the Prior Agreement. 

AGREEMENT 
 NOW, THEREFORE, in consideration of these premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties hereto agree to amend and restate the Prior Agreement in its entirety as set forth herein: 
 SECTION 1. GENERAL.

 1.1 Definitions. As used in this Agreement the following terms shall have the
following respective meanings: 
 (a) “Common Stock” means the
Company’s Common Stock, $0.0001 par value. 
 (b) “Exchange Act”
means the Securities Exchange Act of 1934, as amended. 
 (c) “Form
S-3” means such form under the Securities Act as in effect on the date hereof or any successor or similar registration form under the Securities Act subsequently adopted by the SEC which permits inclusion or incorporation
of substantial information by reference to other documents filed by the Company with the SEC. 

  
 1. 

 (d) “Holder” means any Investor owning of
record Registrable Securities that have not been sold to the public or any assignee of record of such Registrable Securities in accordance with Section 2.9 hereof. 

(e) “Initial Offering” means the Company’s first firm commitment underwritten public
offering of the Common Stock registered under the Securities Act. 
 (f)
“Register,” “registered,” and “registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the
declaration or ordering of effectiveness of such registration statement or document. 
 (g)
“Registrable Securities” means (a) Common Stock issuable or issued upon conversion of the Shares and (b) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right or other
security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, such above-described securities. Notwithstanding the foregoing, Registrable Securities shall not include any securities
(i) sold by a person to the public either pursuant to a registration statement or Rule 144, (ii) sold in a private transaction in which the transferor’s rights under Section 2 of this Agreement are not assigned or (iii) held
by a Holder (together with its affiliates) if, as reflected on the Company’s list of stockholders, such Holder (together with its affiliates) holds less than 1% of the outstanding Common Stock (treating all shares of Series Preferred on an
as-if-converted basis), the Company has completed its Initial Offering and all shares of Common Stock issuable or issued upon conversion of the Shares held by and issuable to such Holder (and its affiliates) may be sold pursuant to Rule 144 during
any 90-day period. 
 (h) “Registrable Securities then outstanding” shall be the
number of shares of the Common Stock that are Registrable Securities and either (a) are then issued and outstanding or (b) are issuable pursuant to then exercisable or convertible securities. 

(i) “Registration Expenses” shall mean all expenses incurred by the Company in complying
with Sections 2.2, 2.3 and 2.4 hereof, including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of counsel for the Company, reasonable fees and disbursements of a single special counsel for the
Holders, blue sky fees and expenses, and the expense of any special audits incident to or required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company).

 (j) “Rule 144” shall mean Rule 144 promulgated under the Securities Act.

 (k) “SEC” or “Commission” means the Securities and
Exchange Commission. 
 (l) “Securities Act” shall mean the Securities Act of
1933, as amended. 
 (m) “Selling Expenses” shall mean all stock transfer taxes,
underwriting discounts and selling commissions applicable to the sale. 
 (n) “Series A-1
Stock” shall mean the Company’s Series A-1 Preferred Stock. 

  
 2. 

 (o) “Series Preferred” shall mean the Series
A-1 Stock, the Series A-2 Stock and the Series B Stock. 
 (p) “Shares” shall
mean the Series Preferred held from time to time by the Investors listed on Exhibit A hereto and their permitted assigns and, except for Sections 2.2 and 2.4, the Series A-1 Stock and Series A-2 Stock issuable upon exercise of the
Warrants. 
 (q) “Special Registration Statement” shall mean (i) a
registration statement relating to any employee benefit plan or (ii) with respect to any corporate reorganization or transaction under Rule 145 of the Securities Act, any registration statements related to the issuance or resale of
securities issued in such a transaction or (iii) a registration related to stock issued upon conversion of debt securities. 
 (r) “Warrants” shall mean (i) that certain warrant to purchase Series A-1 Stock held by Forsythe Biotechnology Group, Inc. dated November 1, 2004, (ii) that
certain warrant to purchase Series A-1 Stock held by VenCore Solutions LLC dated December 20, 2005, (iii) that certain warrant to purchase Series A-1 Stock held by VenCore Solutions LLC dated October 13, 2006, (iv) that certain
warrant to purchase Series A-2 Stock held by VenCore Solutions LLC dated June 14, 2007 and (v) that certain warrant to purchase Series A-2 Stock held by TriplePoint Capital LLC dated September 14, 2007. 

SECTION 2. REGISTRATION; RESTRICTIONS ON TRANSFER. 

2.1 Restrictions on Transfer. 

(a) Each Holder agrees not to make any disposition of all or any portion of the Shares or Registrable Securities
unless and until: 
 (i) there is then in effect a registration statement under the Securities Act
covering such proposed disposition and such disposition is made in accordance with such registration statement; or 
 (ii) (A) The transferee has agreed in writing to be bound by the terms of this Agreement, (B) such Holder shall have notified the Company of the proposed disposition and shall have
furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and (C) if reasonably requested by the Company, such Holder shall have furnished the Company with an opinion of counsel, reasonably
satisfactory to the Company, that such disposition will not require registration of such shares under the Securities Act. It is agreed that the Company will not require opinions of counsel for transactions made pursuant to Rule 144, except in
unusual circumstances. After its Initial Offering, the Company will not require any transferee pursuant to Rule 144 to be bound by the terms of this Agreement if the shares so transferred do not remain Registrable Securities hereunder following such
transfer. 
 (b) Notwithstanding the provisions of subsection (a) immediately above, no such
restriction shall apply to a transfer by a Holder that is (A) a partnership transferring to its partners or former partners their respective partnership interests in accordance with the terms of the applicable partnership agreement, (B) a
corporation transferring to a wholly-owned subsidiary or a parent 

  
 3. 

 
corporation that owns all of the capital stock of the Holder, (C) a limited liability company transferring to its members or former members their respective interest in the limited liability
company in accordance with the terms of the limited liability company agreement, or (D) an individual transferring to the Holder’s family member or trust for the benefit of an individual Holder; provided that in each case the
transferee will agree in writing to be subject to the terms of this Agreement to the same extent as if he were an original Holder hereunder. 
 (c) Each certificate representing Shares or Registrable Securities shall be stamped or otherwise imprinted with legends substantially similar to the following (in addition to any legend required
under applicable state securities laws): 
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION
OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. 
 THE SALE,
PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN INVESTOR RIGHTS AGREEMENT BY AND BETWEEN THE STOCKHOLDER AND THE COMPANY. COPIES OF SUCH INVESTOR RIGHTS
AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 
 (d) The Company shall
be obligated to reissue promptly unlegended certificates at the request of any Holder thereof if the Company has completed its Initial Offering and the Holder shall have obtained subject to Sections 2.1(a) and 2.1(b) an opinion of counsel (which
counsel may be counsel to the Company) reasonably acceptable to the Company to the effect that the securities proposed to be disposed of may lawfully be so disposed of without registration, qualification and legend; provided, that the second
legend listed above shall be removed only at such time as the Holder of such certificate is no longer subject to any restrictions hereunder. 
 (e) Any legend endorsed on an instrument pursuant to applicable state securities laws and the stop-transfer instructions with respect to such securities shall be removed upon receipt by the Company
of an order of the appropriate blue sky authority authorizing such removal. 

  
 4. 

 2.2 Demand Registration. 

(a) Subject to the conditions of this Section 2.2, if the Company shall receive a written request from the
Holders of at least 20% of the Registrable Securities (the “Initiating Holders”) that the Company file a registration statement under the Securities Act covering the registration of at least 20% of the Registrable Securities
then outstanding (or a lesser percent if the anticipated aggregate offering price, net of underwriting discounts and commissions, is at least $5,000,000), then the Company shall, within 30 days of the receipt thereof, give written notice of such
request to all Holders, and subject to the limitations of this Section 2.2, effect, as expeditiously as reasonably possible, the registration under the Securities Act of all Registrable Securities that all Holders request to be registered.

 (b) If the Initiating Holders intend to distribute the Registrable Securities covered by their request
by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 2.2 or any request pursuant to Section 2.4 and the Company shall include such information in the written notice referred
to in Section 2.2(a) or Section 2.4(a), as applicable. In such event, the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and
the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form
with the underwriter or underwriters selected for such underwriting by the Holders of a majority of the Registrable Securities held by all Initiating Holders (which underwriter or underwriters shall be reasonably acceptable to the Company).
Notwithstanding any other provision of this Section 2.2 or Section 2.4, if the underwriter advises the Company that marketing factors require a limitation of the number of securities to be underwritten (including Registrable Securities)
then the Company shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares that may be included in the underwriting shall be allocated to the Holders of such Registrable
Securities on a pro rata basis based on the number of Registrable Securities held by all such Holders (including the Initiating Holders); provided, however, that the number of shares of Registrable Securities to be included in such
underwriting and registration shall not be reduced unless all other securities of the Company are first entirely excluded from the underwriting and registration; provided further, that if such reduction shall reduce the amount of Registrable
Securities held by such Holders to be included in such underwriting and registration below 50% of the total amount of Registrable Securities requested to be included in such registration by the Initiating Holders, then such registration shall not be
counted as a registration effected pursuant to Section 2.2 or Section 2.4. Any Registrable Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration. 

(c) The Company shall not be required to effect a registration pursuant to this Section 2.2: 

(i) prior to the earlier of (A) the third anniversary of the date of this Agreement or (B) of the
expiration of the restrictions on transfer set forth in Section 2.11 following the Initial Offering; 

(ii) after the Company has effected two registrations pursuant to this Section 2.2, such registrations have
been declared or ordered effective, there are no stop orders in effect and the Company has otherwise complied with its obligations set forth in Section 2.6 hereof with respect to such registrations, each at the time of any subsequent request to
effect any additional registration pursuant to this Section 2.2; 

  
 5. 

 (iii) during the period starting with the date of filing of, and
ending on the date 180 days following the effective date of the registration statement pertaining to the Initial Offering (or such longer period as may be determined pursuant to Section 2.11 hereof); provided that the Company makes
reasonable good faith efforts to cause such registration statement to become effective; 
 (iv) if
within 30 days of receipt of a written request from Initiating Holders pursuant to Section 2.2(a), the Company gives notice to the Holders of the Company’s intention to file a registration statement for its Initial Offering within 90 days
of the time of the Company’s receipt of such written request in which the Initiating Holders have been or will be permitted to include all the Registrable Securities so requested to be registered, subject to Section 2.2(b); 

(v) if the Company shall furnish to Holders requesting a registration statement pursuant to this Section 2.2
a certificate signed by the Chairman of the Board stating that in the good faith judgment of the Board of Directors of the Company (the “Board”), it would be seriously detrimental to the Company and its stockholders for such
registration statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than 90 days after receipt of the request of the Initiating Holders; provided that such right to
delay a request under this Section 2.2(c)(v) (together with any similar right in the case of a registration under Section 2.4) shall be exercised by the Company not more than twice in any 12-month period; 

(vi) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately
registered on Form S-3 pursuant to a request made pursuant to Section 2.4 below; or 
 (vii)
in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance. 

2.3 Piggyback Registrations. The Company shall notify all Holders of Registrable Securities in writing at least 30
days prior to the filing of any registration statement under the Securities Act for purposes of a public offering of securities of the Company (including, but not limited to, registration statements relating to secondary offerings of securities of
the Company, but excluding Special Registration Statements) and will afford each such Holder an opportunity to include in such registration statement all or part of such Registrable Securities held by such Holder, at such Holder’s election.
Each Holder desiring to include in any such registration statement all or any part of the Registrable Securities held by it shall, within 15 days after the above-described notice from the Company, so notify the Company in writing. Such notice shall
state the intended method of disposition of the Registrable Securities by such Holder. If a Holder decides not to include all of its Registrable Securities in any registration statement thereafter filed by the Company, such Holder shall nevertheless
continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and conditions set
forth herein. 

  
 6. 

 (a) Underwriting. If the registration statement of which the Company
gives notice under this Section 2.3 is for an underwritten offering, the Company shall so advise the Holders of Registrable Securities. In such event, the right of any such Holder to include Registrable Securities in a registration pursuant to
this Section 2.3 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to
distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Company. Notwithstanding any other provision of
this Agreement, if the underwriter determines in good faith that marketing factors require a limitation of the number of shares to be underwritten, the number of shares that may be included in the underwriting shall be allocated, first, to the
Company; second, to the Holders on a pro rata basis based on the total number of Registrable Securities held by the Holders; and third, to any stockholder of the Company (other than a Holder) on a pro rata basis; provided,
however, that no such reduction shall reduce the amount of securities of the selling Holders included in the registration below 20% of the total amount of securities included in such registration, unless such offering is the Initial Offering and
such registration does not include securities of any other selling stockholders, in which event any or all of the Registrable Securities of the Holders may be excluded in accordance with the immediately preceding clause. In no event will shares of
any other selling stockholder be included in such registration that would reduce the number of shares which may be included by Holders without the written consent of Holders of not less than a majority of the Registrable Securities proposed to be
sold in the offering. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter, delivered at least 10 business days prior to the effective date
of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall be excluded and withdrawn from the registration. For any Holder which is a partnership, limited liability company or corporation, the
partners, retired partners, members, retired members and stockholders of such Holder, or the estates and family members of any such partners, retired partners, members and retired members and any trusts for the benefit of any of the foregoing person
shall be deemed to be a single “Holder,” and any pro rata reduction with respect to such “Holder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals
included in such “Holder,” as defined in this sentence. 
 (b) Right to Terminate Registration.
The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.3 whether or not any Holder has elected to include securities in such registration. The Registration Expenses of such withdrawn
registration shall be borne by the Company in accordance with Section 2.5 hereof. 
 2.4 Form S-3
Registration. In case the Company shall receive a written request from any Holder or Holders of Registrable Securities that the Company effect a registration on Form S-3 (or any successor to Form S-3) or any similar short-form
registration statement and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will: 

(a) promptly give written notice of the proposed registration, and any related qualification or compliance, to all
other Holders of Registrable Securities; and 

  
 7. 

 (b) as soon as practicable, effect such registration and all such
qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with
all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within 15 days after receipt of such written notice from the Company; provided, however, that
the Company shall not be obligated to effect any such registration, qualification or compliance pursuant to this Section 2.4: 
 (i) if Form S-3 is not available for such offering by the Holders, or 
 (ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities
(if any) at an aggregate price to the public of less than $1,000,000, or 
 (iii) if within 30 days of
receipt of a written request from any Holder or Holders pursuant to this Section 2.4, the Company gives notice to such Holder or Holders of the Company’s intention to file a registration statement for a public offering within 90 days,
other than pursuant to a Special Registration Statement, or 
 (iv) if the Company shall furnish to the
Holders a certificate signed by the Chairman of the Board stating that in the good faith judgment of the Board, it would be seriously detrimental to the Company and its stockholders for such Form S-3 registration to be effected at such time, in
which event the Company shall have the right to defer the filing of the Form S-3 registration statement for a period of not more than 60 days after receipt of the request of the Holder or Holders under this Section 2.4; provided,
that such right to delay a request under this Section 2.4(b)(iv) (together with any similar right in the case of a registration under Section 2.2) shall be exercised by the Company not more than twice in any 12-month period, or 

(v) if the Company has, within the 12-month period preceding the date of such request, already effected two
registrations on Form S-3 for the Holders pursuant to this Section 2.4, such registrations have been declared or ordered effective, there are no stop orders in effect and the Company has otherwise complied with its obligations set forth in
Section 2.6 hereof with respect to such registrations, each at the time of any subsequent request to effect any additional registration pursuant to this Section 2.4, or 

(vi) in any particular jurisdiction in which the Company would be required to qualify to do business or to
execute a general consent to service of process in effecting such registration, qualification or compliance. 

(c) Subject to the foregoing, the Company shall file a Form S-3 registration statement covering the
Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the requests of the Holders. Registrations effected pursuant to this Section 2.4 shall not be counted as demands for registration
or registrations effected pursuant to Section 2.2. 

  
 8. 

 2.5 Expenses of Registration. Except as specifically provided herein,
all Registration Expenses incurred in connection with any registration, qualification or compliance pursuant to Section 2.2, 2.3 or 2.4 herein shall be borne by the Company. All Selling Expenses incurred in connection with any registrations
hereunder, shall be borne by the holders of the securities so registered pro rata on the basis of the number of shares so registered. The Company shall not, however, be required to pay for expenses of any registration proceeding begun
pursuant to Section 2.2 or 2.4, the request of which has been subsequently withdrawn by the Holders requesting such registration proceeding unless (a) the withdrawal is based upon a material adverse event related to the business,
properties, condition or operations of the Company of which such Holders were not aware at the time of such request (without imputing the knowledge of any non-requesting Holder to any requesting Holders) or (b) the Holders of a majority of
Registrable Securities agree to deem such registration to have been effected as of the date of such withdrawal for purposes of determining whether the Company shall be obligated pursuant to Section 2.2 or 2.4, as applicable, to undertake any
subsequent registration, in which event such right to one requested registration shall be forfeited by all Holders. If the Holders are required to pay the Registration Expenses, such expenses shall be borne by the holders of securities (including
Registrable Securities) requesting such registration in proportion to the number of shares for which registration was requested. If the Company is required to pay the Registration Expenses of a withdrawn offering pursuant to clause (a) above,
then such registration shall not be deemed to have been effected for purposes of determining whether the Company shall be obligated pursuant to Section 2.2 or 2.4, as applicable, to undertake any subsequent registration. 

2.6 Obligations of the Company. Whenever required to effect the registration of any Registrable Securities, the
Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with the SEC a
registration statement with respect to such Registrable Securities and use all reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered
thereunder, keep such registration statement effective for up to 180 days or, if earlier, until the Holder or Holders have completed the distribution related thereto; provided, however, that at any time, upon written notice to the
participating Holders and for a period not to exceed 60 days thereafter (the “Suspension Period”), the Company may delay the filing or effectiveness of any registration statement or suspend the use or effectiveness of any
registration statement (and the Holders hereby agree not to offer or sell any Registrable Securities pursuant to such registration statement during the Suspension Period) if the Company reasonably believes that there is or may be in existence
material nonpublic information or events involving the Company, the failure of which to be disclosed in the prospectus included in the registration statement could result in a Violation (as defined below). In the event that the Company shall
exercise its right to delay or suspend the filing or effectiveness of a registration hereunder, the applicable time period during which the registration statement is to remain effective shall be extended by a period of time equal to the duration of
the Suspension Period. The Company may extend the Suspension Period for an additional consecutive 60 days with the consent of the holders of a majority of the Registrable Securities registered under the applicable registration statement. If so
directed by the 

  
 9. 

 
Company, all Holders registering shares under such registration statement shall (i) not offer to sell any Registrable Securities pursuant to the registration statement during the period in
which the delay or suspension is in effect after receiving notice of such delay or suspension; and (ii) use their best efforts to deliver to the Company (at the Company’s expense) all copies, other than permanent file copies then in such
Holders’ possession, of the prospectus relating to such Registrable Securities current at the time of receipt of such notice. Notwithstanding the foregoing, the Company shall not be required to file, cause to become effective or maintain the
effectiveness of any registration statement other than a registration statement on Form S-3 that contemplates a distribution of securities on a delayed or continuous basis pursuant to Rule 415 under the Securities Act. 

(b) Prepare and file with the SEC such amendments and supplements to such registration statement and the
prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for the period set forth
in subsection (a) above. 
 (c) Use its reasonable efforts to register and qualify the securities
covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided that the Company shall not be required in connection therewith or as a
condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions. 
 (d) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter(s) of such
offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement; provided, however, each Holder’s (i) representations and warranties thereunder shall be limited to
matters respecting its ownership of the Registrable Securities and such other information it adds to the registration statement regarding itself, and (ii) indemnification thereunder shall be (x) limited to the information in item
(i) immediately above, and be expressly subject to the net proceeds from the offering received by such Holder in the offering, and (y) shall be a several obligation of such Holder (and shall not be a joint and several obligation of all of
the Holders). 
 (e) Notify each Holder of Registrable Securities covered by such registration statement
at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue
statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. The Company will amend or supplement such
prospectus in order to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the
circumstances then existing. 

  
 10.

 (f) Use its reasonable efforts to furnish, on the date that such
Registrable Securities are delivered to the underwriters for sale, if such securities are being sold through underwriters, (i) an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in
form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and (ii) a letter, dated as of such date, from the independent certified public accountants of the Company, in
form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering addressed to the underwriters. 

(g) Make generally available to its security holders, and to deliver to each Holder participating in the
registration statement, an earnings statement of the Company that will satisfy the provisions of Section 11(a) of the Securities Act covering a period of 12 months beginning after the effective date of such registration statement as soon as
reasonably practicable after the termination of such 12-month period. 
 2.7 Delay of Registration;
Furnishing Information. 
 (a) No Holder shall have any right to obtain or seek an injunction
restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

(b) It shall be a condition precedent to the obligations of the Company to take any action pursuant to
Sections 2.2, 2.3 or 2.4 that the selling Holders shall furnish to the Company such information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such securities as shall be required to
effect the registration of their Registrable Securities. 
 (c) The Company shall have no obligation with
respect to any registration requested pursuant to Section 2.2 or Section 2.4 if the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the
number of shares or the anticipated aggregate offering price required to originally trigger the Company’s obligation to initiate such registration as specified in Section 2.2 or Section 2.4, whichever is applicable. 

2.8 Indemnification. In the event any Registrable Securities are included in a registration statement under
Sections 2.2, 2.3 or 2.4: 
 (a) The Company will indemnify and hold harmless each Holder, the
partners, members, officers and directors of each Holder, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who, directly or indirectly, controls, is controlled by or is under common control with such Holder
or underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint or several) (or actions in respect thereto) to which any of the foregoing entities or persons may become subject
under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any of the following statements, omissions or violations
(collectively a “Violation”) by the Company: (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement or incorporated by reference therein, including any
preliminary prospectus 

  
 11.

 
or final prospectus contained therein or otherwise filed with the SEC or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact
required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation
promulgated under the Securities Act, the Exchange Act or any state securities law in connection with the offering covered by such registration statement; and the Company will reimburse each such Holder, partner, member, officer, director,
underwriter or control person for any legal or other expenses reasonably incurred by any of them in connection with investigating or defending any such loss, claim, damage, liability or action; provided however, that the indemnity agreement
contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company, which consent shall not be unreasonably
withheld or delayed, nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written
information furnished expressly for use in connection with such registration by such Holder, partner, member, officer, director, underwriter or control person of such Holder. 

(b) Each Holder will, if Registrable Securities held by such Holder are included in the securities as to which
such registration qualifications or compliance is being effected, severally and not jointly and severally, indemnify and hold harmless the Company, each of its directors, its officers and each person, if any, who, directly or indirectly, controls,
is controlled by or is under common control with the Company within the meaning of the Securities Act, any underwriter and any other Holder selling securities under such registration statement or any of such other Holder’s partners, members,
directors or officers or any person who, directly or indirectly, controls, is controlled by or is under common control with such Holder, against any losses, claims, damages or liabilities (joint or several) (or actions in respect thereto) to which
the Company or any such director, officer, control person, underwriter or other such Holder, or partner, member, director, officer or control person of such other Holder may become subject under the Securities Act, the Exchange Act or other federal
or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any of the following statements: (i) any untrue statement or alleged untrue statement of a material fact
contained in such registration statement or incorporated by reference therein, including any preliminary prospectus or final prospectus contained therein or otherwise filed with the SEC or any amendments or supplements thereto, (ii) the
omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act
(collectively, a “Holder Violation”), in each case to the extent (and only to the extent) that such Holder Violation occurs in reliance upon and in conformity with written information furnished by such Holder under an
instrument duly executed by such Holder and stated to be specifically for use in connection with such registration; and each such Holder will reimburse any legal or other expenses reasonably incurred by the Company or any such director, officer,
control person, underwriter or other Holder, or partner, member, officer, director or control person of such other Holder in connection with investigating or defending any such loss, claim, damage, liability or action if it is judicially determined
that there was such a Holder Violation; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such
settlement is 

  
 12.

 
effected without the consent of the Holder, which consent shall not be unreasonably withheld or delayed; provided further, that in no event shall any indemnity under this Section 2.8
exceed the net proceeds from the offering received by such Holder. 
 (c) Promptly after receipt by an
indemnified party under this Section 2.8 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Section 2.8, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other
indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and expenses
thereof to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any
other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the
indemnified party under this Section 2.8 to the extent, and only to the extent, prejudicial to its ability to defend such action, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that
it may have to any indemnified party otherwise than under this Section 2.8. 
 (d) If the
indemnification provided for in this Section 2.8 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying party, in
lieu of indemnifying such indemnified party thereunder, shall to the extent permitted by applicable law contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is
appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the Violation(s) or Holder Violation(s) that resulted in such loss, claim, damage or liability, as well
as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a
material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or
prevent such statement or omission; provided, that in no event shall any contribution by a Holder hereunder exceed the net proceeds from the offering received by such Holder. 

(e) The obligations of the Company and Holders under this Section 2.8 shall survive completion of any
offering of Registrable Securities in a registration statement and, with respect to liability arising from an offering to which this Section 2.8 would apply that is covered by a registration filed before termination of this Agreement, such
termination. No indemnifying party, in the defense of any such claim or litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. 

  
 13.

 2.9 Assignment of Registration Rights. The rights to cause the
Company to register Registrable Securities pursuant to this Section 2 may be assigned by a Holder to a transferee or assignee of Registrable Securities (for so long as such shares remain Registrable Securities) that (a) is a subsidiary,
parent, general partner, limited partner, retired partner, member or retired member, or stockholder of a Holder that is a corporation, partnership or limited liability company, (b) is a Holder’s family member or trust for the benefit of an
individual Holder, (c) acquires at least 100,000 shares of Registrable Securities (as adjusted for stock splits and combinations), or (d) is an entity affiliated by common control (or other related entity) with such Holder; provided,
however, that transfers to a Holder’s partners, former partners, members, former members, stockholders or affiliates who are originally a party to this Agreement shall not require a minimum amount of shares of Registrable Securities to be
transferred; provided, further, (i) the transferor shall, within 10 days after such transfer, furnish to the Company written notice of the name and address of such transferee or assignee and the securities with respect to which such
registration rights are being assigned and (ii) such transferee shall agree to be subject to all restrictions set forth in this Agreement. 

2.10 Limitation on Subsequent Registration Rights. Other than as provided in
Section 5.10, after the date of this Agreement, the Company shall not, without the written consent of Holders of at least
66 2/3% of the Registrable Securities then
outstanding, voting together as a single class on an as-converted basis, enter into any agreement with any holder or prospective holder of any securities of the Company that would (i) grant such holder rights (a) to demand the registration
of shares of the Company’s capital stock or (b) to include such shares in a registration statement that would reduce the number of shares includable by the Holders, (ii) grant any registration rights unless such holder is bound by
obligations similar to the obligations of the Holders set forth in Sections 2.5, 2.7, 2.8, 2.11 and 2.12 or (iii) otherwise conflict with the registration rights granted to the Holders pursuant to this Agreement. 

2.11 “Market Stand-Off” Agreement. Each Holder hereby agrees that such Holder shall not sell, transfer,
make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Common Stock (or other securities of the Company) held by such Holder (other than those
included in the registration or those acquired in or following the Initial Offering) for a period specified by the representative of the underwriters of Common Stock (or other securities of the Company) not to exceed 180 days following the effective
date of the Initial Offering (or such longer period after the expiration of the 180-day period, as the underwriters or the Company shall request in order to comply with NASD Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or
regulation); provided, that all officers and directors of the Company (and any entities affiliated with such directors) are bound by and have entered into similar agreements for the same period of time. 

2.12 Agreement to Furnish Information. Each Holder agrees to execute and deliver such other agreements as may be
reasonably requested by the Company or the underwriter that are consistent with the Holder’s obligations under Section 2.11 or that are necessary to give further effect thereto. In addition, if requested by the Company or the
representative of the underwriters of Common Stock (or other securities of the Company) in writing, each Holder shall provide, within 10 days of such request, such information as may be required by the Company or such representative in connection
with the completion of any public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act. The obligations described in Section 2.11 

  
 14.

 
and this Section 2.12 shall not apply to a Special Registration Statement. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities
of the Company) subject to the foregoing restriction until the end of said 10-day period. Each Holder agrees that any transferee of any shares of Registrable Securities shall be bound by Sections 2.11 and 2.12. The underwriters of the
Company’s stock are intended third party beneficiaries of Sections 2.11 and 2.12 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 

2.13 Rule 144 Reporting. With a view to making available to the Holders the benefits of certain rules and
regulations of the SEC which may permit the sale of the Registrable Securities to the public without registration, the Company agrees to use its best efforts to: 

(a) Make and keep public information available, as those terms are understood and defined in Rule 144 or any
similar or analogous rule promulgated under the Securities Act, at all times after the effective date of the first registration filed by the Company for an offering of its securities to the general public; 

(b) File with the SEC, in a timely manner, all reports and other documents required of the Company under the
Exchange Act; and 
 (c) So long as a Holder owns any Registrable Securities, furnish to such Holder
forthwith upon request: a written statement by the Company as to its compliance with the reporting requirements of Rule 144 and of the Exchange Act (at any time after it has become subject to such reporting requirements); a copy of the most recent
annual or quarterly report of the Company filed with the Commission; and such other reports and documents as a Holder may reasonably request in connection with availing itself of any rule or regulation of the SEC allowing it to sell any such
securities without registration. 
 SECTION 3. COVENANTS OF THE COMPANY. 

3.1 Basic Financial Information and Reporting. 

(a) The Company will maintain true books and records of account in which full and correct entries will be made of
all its business transactions pursuant to a system of accounting established and administered in accordance with generally accepted accounting principles consistently applied (except as noted therein or as disclosed to the recipients thereof), and
will set aside on its books all such proper accruals and reserves as shall be required under generally accepted accounting principles consistently applied. 
 (b) So long as an Investor (with its affiliates) holds any shares of Registrable Securities (a “Current Investor”), the Company will furnish each such Current Investor, as
soon as practicable after the end of each fiscal year of the Company, and in any event within 90 days thereafter, a balance sheet of the Company, as at the end of such fiscal year, and a statement of income and a statement of cash flows of the
Company, for such year, all prepared in accordance with generally accepted accounting principles consistently applied (except as noted therein or as disclosed to the recipients thereof) and setting forth in each case in comparative form the figures
for the previous fiscal year, all in reasonable detail. The Company will also furnish each Current Investor, as soon as 

  
 15.

 
practicable after the end of each fiscal year of the Company, and in any event within 150 days thereafter, such financial statements accompanied by a report and opinion thereon by independent
public accountants of national standing selected by the Board. 
 (c) The Company will furnish each
Current Investor, as soon as practicable after the end of the first, second and third quarterly accounting periods in each fiscal year of the Company, and in any event within 45 days thereafter: (i) a balance sheet of the Company as of the end
of each such quarterly period, and a statement of income and a statement of cash flows of the Company for such period and for the current fiscal year to date, prepared in accordance with generally accepted accounting principles consistently applied
(except as noted therein or as disclosed to the recipients thereof), with the exception that no notes need be attached to such statements and year-end audit adjustments may not have been made. 

(d) The Company will furnish each Current Investor (i) at least 30 days prior to the beginning of each fiscal
year an annual budget and operating plans for such fiscal year (and as soon as available, any subsequent written revisions thereto) and (ii) as soon as practicable after the end of each month, and in any event within 30 days thereafter, a
balance sheet of the Company as of the end of each such month, and a statement of income and a statement of cash flows of the Company for such month and for the current fiscal year to date, prepared in accordance with generally accepted accounting
principles consistently applied (except as noted thereon or as disclosed to the recipients thereof), with the exception that no notes need be attached to such statements and year-end audit adjustments may not have been made. 

3.2 Inspection Rights. Each Current Investor shall have the right to visit and inspect any of the properties of
the Company or any of its subsidiaries, and to discuss the affairs, finances and accounts of the Company or any of its subsidiaries with its officers, and to review such information as is reasonably requested all at such reasonable times and as
often as may be reasonably requested; provided, however, that the Company shall not be obligated under this Section 3.2 with respect to a competitor of the Company or with respect to information which the Board determines in good faith
is highly confidential or attorney-client privileged and should not, therefore, be disclosed, unless such Current Investor signs a nondisclosure agreement in a form reasonably acceptable to the Company. 

3.3 Confidentiality of Records. Each Investor agrees to use the same degree of care as such Investor uses to
protect its own confidential information to keep confidential any information furnished to such Investor that the Company identifies as being confidential or proprietary (so long as such information provided pursuant to this Agreement is not in the
public domain), except that such Investor may disclose such proprietary or confidential information (i) to any partner, subsidiary or parent of such Investor as long as such partner, subsidiary or parent is advised of the confidentiality of
such information; (ii) at such time as it enters the public domain through no fault of such Investor; (iii) that is communicated to it free of any obligation of confidentiality; (iv) that is developed by Investor or its agents
independently of and without reference to any confidential information communicated by the Company; or (v) as required by applicable law. Notwithstanding anything to the contrary contained herein, this Section 3.3 shall not be construed to
limit the right of such Investor or its affiliated entities to develop (directly or indirectly) independently or acquire (directly or indirectly) products or services without use of the Company’s confidential information. The Company
acknowledges that 

  
 16.

 
such Investor or its affiliated entities may currently or in the future be developing information internally, or receiving information from other parties, that is similar to the confidential
information received from the Company. Accordingly, nothing in this Section 3.3 will prohibit such Investor or its affiliated entities from developing or having developed for it products, concepts, systems or techniques that are similar to or
compete with the products, concepts, systems or techniques contemplated by or embodied in the confidential information of the Company. 
 3.4 Reservation of Common Stock. The Company will at all times reserve and keep available, solely for issuance and delivery upon the conversion of the Series Preferred, all Common Stock issuable
from time to time upon such conversion. 
 3.5 Stock Vesting. Unless otherwise approved by the Board
(including at least one of the directors designated by the holders of Series Preferred), all stock options, Common Stock, and other stock equivalents issued after the date of this Agreement to employees, officers, directors, consultants and other
service providers shall be subject to vesting as follows: (a) 25% of such stock shall vest at the end of the first year following the earlier of the date of issuance or such person’s services commencement date with the company, and
(b) 75% of such stock shall vest over the next three years on a monthly basis. Unless otherwise approved by the Board (including at least one of the directors designated by the holders of Series Preferred), any unvested stock issuable or issued
upon exercise of such stock options or other stock equivalents at the time of termination of continuous service (for any reason) to the Company shall be subject to repurchase by the Company at the lower of (i) the original price per share paid
by for such stock or (ii) the fair market value per share of such stock as of the date of such repurchase, as determined in good faith by the Board. 
 3.6 Director and Officer Insurance. The Company will obtain and maintain in full force and effect director and officer liability insurance in an amount determined by the Board. 

3.7 Proprietary Information and Inventions Agreement. The Company has and shall continue to require all employees,
consultants and advisors to execute and deliver a Proprietary Information and Inventions Agreement substantially in a form approved by the Board. 
 3.8 Board Matters. The Company shall reimburse members of the Board for usual and reasonable out of pocket expenses for travel and lodging for their attendance at Board meetings (or any committees
thereof) and reasonable expenses incurred while working for the benefit of the Company. The Board shall meet at least once during each quarter. 
 3.9 Executive Chairman. The Board shall appoint an Executive Chairman (the “Executive Chairman”), who shall be one of the directors appointed by the holders of the Common
Stock and Series Preferred, voting together as a single class on an as-if-converted basis (an “Independent Director”), and shall initially be David S. Kabakoff, Ph.D. The Executive Chairman shall work on behalf of the Company
approximately one day per week and shall be compensated for such service as determined by the Compensation Committee of the Board, or if no such committee exists, by the disinterested members of the Board. 

  
 17.

 3.10 Independent Director Compensation. With the exception of the
Executive Chairman, any compensation provided to any Independent Director shall be provided to each other Independent Director. 
 3.11 Key Man Insurance. The Company shall obtain and maintain in full force and effect term key-person life insurance in the amount of $1,000,000 on the life of Jeffrey Stein, Ph.D., naming the
Company as beneficiary. 
 3.12 Qualified Small Business Stock Status. In the event that the Company
proposes to take an action or engage in a transaction that would reasonably be expected to result in the Shares no longer being “qualified small business stock” within the meaning of Section 1202(c) of the Internal Revenue Code of
1986, as amended (the “Code”), the Company shall notify the Investors and consult in good faith to devise a mutually agreeable and reasonable alternative course of action or transaction structure that would preserve such
status. In addition, the Company shall submit to the Investors and to the Internal Revenue Service any reports that may be required under Section 1202(d)(1)(C) of the Code and any related Treasury Regulations. In addition, within ten
(10) days after any Investor has delivered to the Company a written request therefor, the Company shall deliver to such Investor a written statement informing the Investor whether, in the Company’s good-faith judgment after a reasonable
investigation, such Investor’s interest in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code, or would constitute “qualified small business stock,” if determination of
whether stock constitutes “qualified small business stock” were made by taking into account the modifications set forth in Section 1045(b)(4) of the Code. The Company’s obligation to furnish a written statement pursuant to this
Section 3.12 shall continue notwithstanding the fact that a class of the Company’s stock may be traded on an established securities market. 
 3.13 Market Stand-off Provision. Unless otherwise approved by the Board, the Company shall cause each future holder of its securities to enter into an agreement substantially similar to the lock-up
agreement set forth in Section 2.11 hereof. 
 3.14 Right of First Refusal. The Company shall cause
each future holder of the Company’s Common Stock (other than shares of Common Stock issued or issuable upon conversion of Preferred Stock) to be subject to a right of first refusal in favor of the Company, which the Company shall assign to the
Investors on a pro-rata basis in the event it is not exercised in full by the Company, subject to overallotment rights of the fully-participating Investors. 
 3.15 TriplePoint Loan. The Board shall approve all indebtedness incurred pursuant to that certain Plain English Growth Capital Loan and Security Agreement dated September 14, 2007 by and
between the Company and TriplePoint Capital LLC. 
 3.16 Termination of Covenants. All covenants of the
Company contained in Section 3 of this Agreement (other than the provisions of Section 3.3 and 3.6) shall expire and terminate as to each Investor upon the earlier of (i) the effective date of the registration statement pertaining to
an Initital Offering or (ii) an Acquisition or Asset Transfer (each as defined in the Company’s Amended and Restated Certificate of Incorporation as in effect as of the date hereof (the “Restated Charter”))
(excluding an Acquisition or Asset Transfer by a privately-held entity in which the consideration includes equity securities of such entity). 

  
 18.

 SECTION 4. RIGHTS OF FIRST REFUSAL. 

4.1 Subsequent Offerings. Subject to applicable securities laws, each Current Investor shall have a right of first
refusal to purchase its pro rata share of all Equity Securities, as defined below, that the Company may, from time to time, propose to sell and issue after the date of this Agreement, other than the Equity Securities excluded by
Section 4.6 hereof. Each Current Investor’s pro rata share is equal to the ratio of (a) the number of shares of the Common Stock (including all shares of Common Stock issuable or issued upon conversion of the Shares) of which
such Current Investor is deemed to be a holder immediately prior to the issuance of such Equity Securities to (b) the total number of shares of the outstanding Common Stock (including all shares of Common Stock issued or issuable upon
conversion of the Shares) immediately prior to the issuance of the Equity Securities. The term “Equity Securities” shall mean (i) any Common Stock, Preferred Stock or other security of the Company, (ii) any security
convertible into or exercisable or exchangeable for, with or without consideration, any Common Stock, Preferred Stock or other security of the Company (including any option to purchase such a convertible security), (iii) any security carrying
any warrant or right to subscribe to or purchase any Common Stock, Preferred Stock or other security of the Company or (iv) any such warrant or right. 
 4.2 Exercise of Rights. If the Company proposes to issue any Equity Securities, it shall give each Current Investor written notice of its intention, describing the Equity Securities, the price and
the terms and conditions upon which the Company proposes to issue the same. Each Current Investor shall have 20 days from the giving of such notice to agree to purchase its pro rata share of the Equity Securities for the price and upon the
terms and conditions specified in the notice by giving written notice to the Company and stating therein the quantity of Equity Securities to be purchased. Notwithstanding the foregoing, the Company shall not be required to offer or sell such Equity
Securities to any Current Investor who would cause the Company to be in violation of applicable federal securities laws by virtue of such offer or sale. 
 4.3 Issuance of Equity Securities to Other Persons. If not all of the Current Investors elect to purchase their pro rata share of the Equity Securities, then the Company shall
promptly notify in writing the Current Investors who do so elect (“Fully Exercising Investors”) and shall offer such Fully Exercising Investors the right to acquire such unsubscribed shares on a pro rata basis equal to
the ratio of (a) the number of shares of the Common Stock (including all shares of Common Stock issuable or issued upon conversion of the Shares) of which such Fully Exercising Investor is deemed to be a holder immediately prior to the issuance
of such Equity Securities to (b) the total number of shares of the Common Stock (including all shares of Common Stock issued or issuable upon conversion of the Shares) then held by all Fully-Exercising Investors who wish to purchase some of the
unsubscribed shares. The Fully Exercising Investors shall have five days after receipt of such notice to notify the Company of its election to purchase all or a portion thereof of the unsubscribed shares. The Company shall have 90 days thereafter to
sell the Equity Securities in respect of which the Current Investor’s rights were not exercised, at the same price and upon the same terms and conditions to the purchasers thereof as specified in the Company’s notice to the Current
Investors pursuant to Section 4.2 hereof. If the Company has not sold such 

  
 19.

 
Equity Securities within 90 days of the notice provided pursuant to Section 4.2, the Company shall not thereafter issue or sell any Equity Securities, without first offering such securities
to the Current Investors in the manner provided above. 
 4.4 Termination and Waiver of
Rights of First Refusal. The rights of first refusal established by this Section 4 shall not apply to, and shall terminate upon the earlier of (i) the effective date of the registration statement pertaining to a Qualified Public
Offering (as defined in the Restated Charter), (ii) an Acquisition or Asset Transfer (excluding an Acquisition or Asset Transfer by a privately-held entity in which the consideration includes equity securities of such entity) or
(iii) solely with respect to any Current Investor, the date on which such Current Investor is offered a right of first refusal in accordance with Section 4 and elects not to exercise such right. Notwithstanding Section 5.5 hereof, the
rights of first refusal established by this Section 4 may be amended, or any provision waived with and only with the written consent of the Company and the Current Investors holding at least 66 2/3% of the Registrable Securities held by all Current Investors,
voting together as a single class on an as-converted basis, or as permitted by Section 5.5; provided that, no amendment or waiver shall adversely affect the rights of any Investor with respect to any series of Series Preferred held by
such Investor in a manner differently than the rights of other Investors with respect to such series of Series Preferred, unless such amendment or waiver is agreed to in writing by such adversely affected Investor; provided further that each
Current Investor shall receive notice of such amendment or waiver within a reasonable period of time following the effectiveness of such amendment or waiver. 

4.5 Assignment of Rights of First Refusal. The rights of first refusal of each Current Investor under this
Section 4 may be assigned to the same parties provided for with respect to any transfer of registration rights pursuant to Section 2.9, subject to the same restrictions set forth therein. 

4.6 Excluded Securities. The rights of first refusal established by this Section 4 shall have no application
to any of the following Equity Securities: 
 (a) Equity Securities issued upon conversion of the Series
Preferred; 
 (b) any Equity Securities issued in connection with any stock split, stock dividend, stock
distribution or recapitalization by the Company; 
 (c) Equity Securities issued after the date of this
Agreement to employees, officers or directors of, or consultants or advisors to the Company pursuant to stock purchase or stock option plans or other arrangements that either (1) exist as of the date of this Agreement and have been approved by
the Board or (2) are approved after the date of this Agreement by the Board; 
 (d) Equity
Securities issued or issuable pursuant to any rights or agreements, options, warrants or convertible securities outstanding as of the date of this Agreement; and Equity Securities issued pursuant to any such rights or agreements granted after the
date of this Agreement, so long as the rights of first refusal established by this Section 4 were complied with, waived, or were inapplicable pursuant to any provision of this Section 4.6 with respect to the initial sale or grant by the
Company of such rights or agreements; 

  
 20.

 (e) any Equity Securities issued for consideration other than cash
pursuant to a merger, consolidation, acquisition, strategic alliance or similar business combination approved by the Board, including the approval of a majority of the directors elected by the holders of the Series Preferred (the
“Preferred Directors”); 
 (f) any Equity Securities issued pursuant to any
equipment loan or leasing arrangement, real property leasing arrangement, or debt financing from a bank or similar financial institution approved by the Board, including the approval of a majority of the Preferred Directors; 

(g) any Equity Securities issued to third-party service providers in exchange for or as partial consideration for
services rendered to the Company approved by the Board; 
 (h) any Equity Securities issued in connection
with strategic transactions involving the Company and other entities, including, without limitation, (i) joint ventures, manufacturing, marketing or distribution arrangements or (ii) technology transfer or development arrangements;
provided that such transactions are primarily for purposes other than raising capital and the terms of such business relationship with such entity have been approved by the Board, including the approval of a majority of the Preferred
Directors; 
 (i) any Equity Securities issued in connection with a Qualified Public Offering; and

 (j) any Series B Stock issued by the Company pursuant to the terms of the Purchase Agreement.

 SECTION 5. MISCELLANEOUS. 

5.1 Governing Law. This Agreement shall be governed by and construed under the laws of the State of California in
all respects as such laws are applied to agreements among California residents entered into and to be performed entirely within California, without reference to conflicts of laws or principles thereof. The parties agree that any action brought by
either party under or in relation to this Agreement, including without limitation to interpret or enforce any provision of this Agreement, shall be brought in, and each party agrees to and does hereby submit to the jurisdiction and venue of, any
state or federal court located in the County of San Diego, California. 
 5.2 Successors and Assigns.
Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the parties hereto and their respective successors, assigns, heirs, executors, and administrators and shall inure to the
benefit of and be enforceable by each person who shall be a holder of Registrable Securities from time to time; provided, however, that prior to the receipt by the Company of adequate written notice of the transfer of any Registrable
Securities specifying the full name and address of the transferee, the Company may deem and treat the person listed as the holder of such shares in its records as the absolute owner and holder of such shares for all purposes, including the payment
of dividends or any redemption price. 

  
 21.

 5.3 Entire Agreement. This Agreement, the
Exhibits and Schedules hereto, the Purchase Agreement and the other documents delivered pursuant thereto constitute the full and entire understanding and agreement between the parties with regard to the granting by the Company of information rights,
registration rights and rights of first refusal to certain Investors and no party shall be liable or bound to any other in any manner by any oral or written representations, warranties, covenants and agreements except as specifically set forth
herein and therein. Each party expressly represents and warrants that it is not relying on any oral or written representations, warranties, covenants or agreements outside of this Agreement. The Company and holders of at least 66 2/3% of the Registrable Securities (as defined in the Prior Agreement)
held by Investors who are parties to the Prior Agreement hereby agree, as evidenced by their signatures hereto, that all rights granted and covenants made under the Prior Agreement are hereby waived, released, terminated and superseded in their
entirety and shall have no further force or effect whatsoever. The rights and covenants provided herein set forth the sole and entire agreement between the parties hereto with respect to the subject matter hereof. 

5.4 Severability. In the event one or more of the provisions of this Agreement should, for any reason, be held to
be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable
provision had never been contained herein. 
 5.5 Amendment and Waiver. 

(a) Except as otherwise expressly provided, this Agreement may be amended or modified, and the
obligations of the Company and the rights of the Holders under this Agreement may be waived, only upon the written consent of the Company and the holders of at least
66 2/3% of the Registrable Securities then
outstanding, voting together as a single class on an as-converted basis; provided that, that no amendment or waiver shall adversely affect the rights of any Investor with respect to any series of Series Preferred held by such Investor in a
manner differently than the rights of other Investors with respect to such series of Series Preferred, unless such amendment or waiver is agreed to in writing by such adversely affected Investor; provided further that each Current Investor
shall receive notice of such amendment or waiver within a reasonable period of time following the effectiveness of such amendment or waiver. 
 (b) For the purposes of determining the number of Holders or Investors entitled to vote or exercise any rights hereunder, the Company shall be entitled to rely solely on the list of record holders
of its stock as maintained by or on behalf of the Company. 
 5.6 Delays or Omissions. It is agreed that
no delay or omission to exercise any right, power, or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a
waiver of any such breach, default or noncompliance, or any acquiescence therein, or of any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent, or approval of any kind or character on
any party’s part of any breach, default or noncompliance under the Agreement or any waiver on such party’s part of any provisions or conditions of this Agreement must be in writing and shall be effective only to the extent specifically set
forth in such writing. All remedies, either under this Agreement, by law, or otherwise afforded to any party, shall be cumulative and not alternative. 

  
 22.

 5.7 Notices. All notices required or permitted hereunder shall be in
writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified; (b) upon receipt of confirmation of delivery, when sent by confirmed electronic mail or facsimile if sent during normal business
hours of the recipient; if not, then on the next business day; (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (d) one day after deposit with a nationally recognized
overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the party to be notified at the address as set forth on the signature pages hereof or Exhibit A hereto or at such other
address or electronic mail address as such party may designate by 10 days advance written notice to the other parties hereto. Upon the request of a party, courtesy copies of any notice required in connection with this Agreement shall be provided to
such party’s legal counsel; provided, however, that delivery to such party’s legal counsel shall have no bearing on the effectiveness of such notice. 

5.8 Attorneys’ Fees. In the event that any suit or action is instituted under or in relation to this
Agreement, including without limitation to enforce any provision in this Agreement, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party
under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals. 

5.9 Titles and Subtitles. The titles of the sections and subsections of this Agreement are for convenience of
reference only and are not to be considered in construing this Agreement. 
 5.10 Additional Investors.
Notwithstanding anything to the contrary contained herein, if the Company shall issue Equity Securities in accordance with Section 4.6(e), (f), (g) or (h) of this Agreement, any purchaser of such Equity Securities may become a party
to this Agreement by executing and delivering an additional counterpart signature page to this Agreement and shall be deemed an “Investor,” a “Holder” and a party hereunder. 

5.11 Counterparts; Facsimile. This Agreement may be executed in any number of counterparts, each of which shall be
an original, but all of which together shall constitute one instrument. Facsimile signatures shall be as effective as original signatures. 
 5.12 Aggregation of Stock. All shares of Registrable Securities or Shares held or acquired by affiliated entities or persons or persons or entities under common management or control shall be
aggregated together for the purpose of determining the availability of any rights under this Agreement. 

5.13 Pronouns. All pronouns contained herein, and any variations thereof, shall be deemed to refer to the
masculine, feminine or neutral, singular or plural, as to the identity of the parties hereto may require. 

5.14 Termination. This Agreement shall terminate and be of no further force or effect upon the earlier of:
(i) an Acquisition or Asset Transfer (excluding an Acquisition or Asset Transfer by a privately-held entity in which the consideration includes equity securities of such entity); or (ii) the date five years following the closing of a
Qualified Public Offering. 

  
 23.

 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 24.

 IN WITNESS
WHEREOF, the parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the
date set forth in the first paragraph hereof. 
  

			
	COMPANY:
	
	TRIUS THERAPEUTICS, INC.
		
	By:	 	 /S/ JEFFREY STEIN

		 	JEFFREY STEIN, PH.D.
		 	President and Chief Executive Officer

			
		
	Address:	 	6310 Nancy Ridge Drive, Suite 101
		 	San Diego, CA 92121

  
 A-1.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	KPCB HOLDINGS, INC., AS NOMINEE
		
	By:	 	 /s/ Brook Byers

		
	Name:	 	 Brook Byers

		
	Title:	 	 Senior Vice President

			
		
	Address:	 	c/o Kleiner, Perkins, Caufield & Byers
		 	2750 Sand Hill Road
		 	Menlo Park, CA 94025

  
 A-2.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	FINTECH GIMV FUND LP
		
	By:	 	FGF (GP) Management Limited
	Its:	 	General Partner
		
	By:	 	 /s/ Denzil Boschat

		 	Denzil Boschat
		 	Director

			
		
	Address:	 	La Motte Chambers,
		 	St Helier
		 	Jersey
		 	Channel Islands
		 	JE1 1BJ

  
 A-3.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	SOFINNOVA VENTURE PARTNERS VII, L.P.
		
	By:	 	Sofinnova Management VII, L.L.C.
		 	its General Partner
		
	By:	 	 /s/ Michael Powell

		 	Michael Powell
		 	Managing General Partner

			
		
	Address:	 	140 Geary Street, 10th Floor
		 	San Francisco, California 94108

  
 A-4.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	INTERWEST PARTNERS IX, LP
		
	By:	 	InterWest Management Partners IX, LLC
		 	its General Partner
		
	By:	 	 /s/ Nina Kjellson

		 	Nina Kjellson
		 	Venture Member

			
		
	Address:	 	2710 Sand Hill Road, Second Floor
		 	Menlo Park, California 94025

  
 A-5.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	VERSANT VENTURE CAPITAL III, L.P.
		
	By:	 	Versant Ventures III, LLC
		 	its General Partner
		
	By:	 	 /s/ Brian G. Atwood

		
	Name:	 	 Brian G. Atwood

		
	Title:	 	 Managing Director

			
		
	Address:	 	3000 Sand Hill Road
		 	Building 4, Suite 210
		 	Menlo Park, California 94025

  

			
	VERSANT SIDE FUND III, L.P.
		
	By:	 	Versant Ventures III, LLC
		 	its General Partner
		
	By:	 	 /s/ Brian G. Atwood

		
	Name:	 	 Brian G. Atwood

		
	Title:	 	 Managing Director

			
		
	Address:	 	3000 Sand Hill Road
		 	Building 4, Suite 210
		 	Menlo Park, California 94025

  
 A-6.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	PRISM VENTURE PARTNERS V, L.P.
		
	By:	 	Prism Investment Partners V, L.P.
		 	its General Partner
		
	By:	 	Prism Venture Partners V, L.L.C.
		 	its General Partner
		
	By:	 	 /s/ Gordie Nye

		 	Managing Director

			
		
	Address:	 	117 Kendrick Street, Suite 200
		 	Needham, MA 02494

  

			
	PRISM VENTURE PARTNERS V-A, L.P.
		
	By:	 	Prism Investment Partners V, L.P.
		 	its General Partner
		
	By:	 	Prism Venture Partners V, L.L.C.
		 	its General Partner
		
	By:	 	 /s/ Gordie Nye

		 	Managing Director

			
		
	Address:	 	117 Kendrick Street, Suite 200
		 	Needham, MA 02494

  
 A-7.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	JIMMY ANKLESARIA AND JENNIFER L. ANKLESARIA FAMILY TRUST UTD
16 JULY 1993
		
	By:	 	 /s/ Jimmy Anklesaria, Co. Trustee

		
	Name:	 	 Jimmy Anklesaria

		
	Title:	 	 Co. Trustee

			
		
	Address:	 	1172 Cuchara Drive
		 	Del Mar, CA 92014

  
 A-8.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	EDGAR F. BERNER TRUST DATED 2/17/89
		
	By:	 	 /s/ Edgar F. Berner

		
	Name:	 	 Edgar F. Berner

		
	Title:	 	 Trustee

			
		
	Address:	 	1230 Inspiration Drive
		 	La Jolla, California 92037

  
 A-9.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	JULIA RICHARDSON BROWN TRUST 1998 U/A DTD 12/18/98
		
	By:	 	 /s/ Julia R. Brown

		
	Name:	 	 Julia R. Brown

		
	Title:	 	 Trustee

			
		
	Address:	 	11480 Forestview Lane
		 	San Diego, California 92131

  
 A-10.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	 /S/ NICHOLAS G. CAVAROCCHI

	NICHOLAS G. CAVAROCCHI

			
		
	Address:	 	 600 Maryland Ave. S.W.

Suite 835 W
 Washington, DC
20024

  
 A-11.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	THE FRANCOIS FERRE AND MAGDA MARQUET TRUST,
AUGUST 1, 1993
		
	By:	 	 /s/ Francois Ferré

		
	Name:	 	 Francois Ferré

		
	Title:	 	 Trustee

			
		
	Address:	 	 8540 Avenida de las Ondas

La Jolla, California 92037

  
 A-12.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	FLORIO FAMILY TRUST DATED JUNE 21, 2002
		
	By:	 	 /s/ Jack J. Florio

		
	Name:	 	 Jack J. Florio

		
	Title:	 	 Trustee

			
		
	Address:	 	 7675 La Jolla Boulevard, Unit #104
 La Jolla, CA 92037

  
 A-13.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	KIYOIZUMI FAMILY TRUST DATED FEBRUARY 6, 2003
		
	By:	 	 /s/ Takashi Kiyoizumi

		
	Name:	 	 Takashi Kiyoizumi

		
	Title:	 	 Trustee

			
		
	Address:	 	 17231 Holly Leaf Court
 San
Diego, California 92127

  
 A-14.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	 /S/ GARY KREMEN

	GARY KREMEN

			
		
	Address:	 	 4019 Goldfinch #137
 San
Diego, California 92103

  
 A-15.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	THE RALPH D. AND SANDRA DEE MAYER FAMILY TRUST
U/D/T DATED 4/23/01
		
	By:	 	 /s/ Ralph J. Mayer

		
	Name:	 	 Ralph J. Mayer

		
	Title:	 	 Trustee

			
		
	Address:	 	 3495 Caminito Daniella
 Del
Mar, California 92014

  
 A-16.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	THE FRANK & BARBARA PETERS FAMILY TRUST DTD
5/96
		
	By:	 	 /s/ Francis X. Peters Jr.

		
	Name:	 	 Francis X. Peters Jr.

		
	Title:	 	 TTEF

			
		
	Address:	 	 3018 Breakers Drive
 Corona
del Mar, California 92625

  
 A-17.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	AMIRALI S. RAJWANY AND DANA R. RAJWANY FAMILY
TRUST
		
	By:	 	 /s/ Amirali S. Rajwany

		
	Name:	 	 Amirali S. Rajwany

		
	Title:	 	 Trustee

			
		
	Address:	 	 5176 Meadows Del Mar
 San
Diego, California 92130

  
 A-18.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	 /S/ HAMILTON SOUTHWORTH
III

	HAMILTON SOUTHWORTH III

			
		
	Address:	 	 1473 Horizon Pointe
 El
Cajon, CA 92020

  
 A-19.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	STRATEGY ADVISORS, LLC DEFINED BENEFIT PLAN
		
	By:	 	 /s/ David S. Kabakoff

		
	Name:	 	 David S. Kabakoff

		
	Title:	 	 Plan Administrator

			
		
	Address:	 	 P.O. Box 9151 (USPS)
 16947
Circa Del Sur (FedEx or UPS)
 Rancho Santa Fe, California 92067

			
	
	DAVID S. & SUSAN O. KABAKOFF FAMILY TRUST DATED
2/24/00
		
	By:	 	 /s/ David S. Kabakoff, Trustee

		
	Name:	 	 David S. Kabakoff

		
	Title:	 	 Trustee

			
		
	Address:	 	 P.O. Box 9151 (USPS)
 16947
Circa Del Sur (FedEx or UPS)
 Rancho Santa Fe, California 92067

  
 A-20.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	JAN S. TUTTLEMAN 2000 TRUST
		
	By:	 	 /s/ Jan Tuttleman

		
	Name:	 	 Jan Tuttleman

		
	Title:	 	 Trustee

			
		
	Address:	 	 7791 Starlight Drive
 La
Jolla, CA 92037

  
 A-21.

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

 

			
	INVESTOR:
	
	 /S/ JEFFREY STEIN

	JEFFREY STEIN, PH.D.

			
		
	Address:	 	 13525 Samantha Avenue
 San
Diego, California 92129

  
 A-22.

 EXHIBIT A 

SCHEDULE OF INVESTORS 
  

					
		 	 NAME AND ADDRESS
	 	
			
		 	 KPCB HOLDINGS, INC., AS NOMINEE

c/o Kleiner, Perkins, Caufield & Byers

2750 Sand Hill Road

Menlo Park, CA 94025

Attention: Risa Stack, Ph.D.
	 	
		 		 	
		 	 FINTECH GIMV FUND LP

La Motte Chambers
 St Helier
 Jersey

Channel Islands
 JE1 1BJ
 Attention: Denzil Boschat
	 	
		 		 	
		 	 SOFINNOVA VENTURE PARTNERS VII, L.P.

140 Geary Street, 10th Floor
 San Francisco, California 94108
 Attention: Michael Powell,
Ph.D.
	 	
		 		 	
		 	 INTERWEST PARTNERS IX, LP

2710 Sand Hill Road, Second Floor

Menlo Park, California 94025

Attention: Nina Kjellson
	 	
		 		 	
		 	 VERSANT VENTURE CAPITAL III, L.P.

3000 Sand Hill Road

Building 4, Suite 210

Menlo Park, California 94025

Attention: Brian G. Atwood
	 	
		 		 	
		 	 VERSANT SIDE FUND III, L.P.

3000 Sand Hill Road

Building 4, Suite 210

Menlo Park, California 94025

Attention: Brian G. Atwood
	 	

  
 A-23.

					
		 	 NAME AND ADDRESS
	 	
			
		 	 PRISM VENTURE PARTNERS V, L.P.

117 Kendrick Street, Suite 200

Needham, MA 02494
 Attention: Brendan O’Leary, Ph.D.
	 	
		 		 	
		 	 PRISM VENTURE PARTNERS V-A, L.P.

117 Kendrick Street, Suite 200

Needham, MA 02494
 Attention: Brendan O’Leary, Ph.D.
	 	
		 		 	
		 	 JAMES N. ADLER

1034 Selby Avenue
 Los Angeles, California 90024-3106
	 	
		 		 	
		 	 EDGAR F. BERNER TRUST DATED 2/17/89

1230 Inspiration Drive

La Jolla, California 92037
	 	
		 		 	
		 	 JULIA RICHARDSON BROWN TRUST 1998 U/A DTD 12/18/98

11480 Forestview Lane

San Diego, California 92131
	 	
		 		 	
		 	 HARBISON FAMILY TRUST U/A 10/21/96

916 Via Panorama
 Palos Verdes Estates, California 90274
	 	
		 		 	
		 	 HANS IMHOF

1215 Emerald Bay
 Laguna Beach, California 92651
	 	
		 		 	
		 	 RAYMOND M. KARAM

2525 Santa Barbara Street

Santa Barbara, California 93105
	 	
		 		 	
		 	 KIYOIZUMI FAMILY TRUST DATED FEBRUARY 6,
2003
 17231 Holly Leaf Court

San Diego, California 92127
	 	

  
 A-24.

					
		 	 NAME AND ADDRESS
	 	
			
		 	 THE GARY KOSTOW PROFIT SHARING &
401(K) PLAN, U/T/D 3/11/05

14820 Caminito Lorren

Del Mar, California 92014
	 	
		 		 	
		 	 JAY KUNIN

1355 Seagrove Street

San Diego, California 92130
	 	
		 		 	
		 	 THE FRANCOIS FERRE AND MAGDA MARQUET
TRUST, AUGUST 1, 1993
 8540 Avenida de las Ondas

La Jolla, California 92037
	 	
		 		 	
		 	 THE RALPH J. AND SANDRA DEE MAYER
FAMILY TRUST U/D/T DATED 4/23/01
 3495 Caminito
Daniella
 Del Mar, California 92014
	 	
		 		 	
		 	 PAPPELBAUM FAMILY TRUST 10/87

1201 Camino del Mar, Suite 202

Del Mar, California 92014
	 	
		 		 	
		 	 THE WILLIAM AND ARDYCE PEEPLES FAMILY
TRUST
 877 Gwyne Avenue

Santa Barbara, California 93111
	 	
		 		 	
		 	 THE FRANK & BARBARA PETERS FAMILY
TRUST DTD 5/96
 3018 Breakers Drive

Corona del Mar, California 92625
	 	
		 		 	
		 	 AMIRALI S. RAJWANY AND DANA R. RAJWANY
FAMILY TRUST
 5176 Meadows Del Mar

San Diego, California 92130
	 	
		 		 	
		 	 JEFFREY STEIN, PH.D.

13525 Samantha Avenue

San Diego, California 92129
	 	

  
 A-25.

					
		 	 NAME AND ADDRESS
	 	
			
		 	 STRATEGY ADVISORS, LLC DEFINED BENEFIT
PLAN
 P.O. Box 9151 (USPS)

16947 Circa Del Sur (FedEx or UPS)

Rancho Santa Fe, California 92067
	 	
		 		 	
		 	 SERAPHIM FUND I, LLC

P.O. Box 16969
 Irvine, California 92623-6969
	 	
		 		 	
		 	 GARY KREMEN

4019 Goldfinch #137

San Diego, California 92103
	 	
		 		 	
		 	 DANIEL EINHORN AND EMILY FELDMAN EINHORN
TRUST OF 1994 U/A DATED 4/13/94
 1655 La Jolla Rancho
Rd.
 La Jolla, California 92037-7846
	 	
		 		 	
		 	 FLORIO FAMILY TRUST DATED JUNE 21,
2002
 7675 La Jolla Boulevard, Unit #104

La Jolla, CA 92037
	 	
		 		 	
		 	 JAN S. TUTTLEMAN 2000 TRUST

7791 Starlight Drive

La Jolla, CA 92037
	 	
		 		 	
		 	 HAMILTON SOUTHWORTH III

1473 Horizon Pointe

El Cajon, CA 92020
	 	
		 		 	
		 	 NICHOLAS G. CAVAROCCHI

316 Pennsylvania Ave. S.E.

Washington, DC 20003
	 	
		 		 	
		 	 JIMMY ANKLESARIA AND JENNIFER L. ANKLESARIA
FAMILY TRUST UTD 16 JULY 1993
 1172 Cuchara
Drive
 Del Mar, CA 92014
	 	

  
 A-26.

					
		 	 NAME AND ADDRESS
	 	
			
		 	 DAVID S. & SUSAN O. KABAKOFF FAMILY TRUST
DATED 2/24/00
 P.O. Box 9151

Rancho Santa Fe, CA 92067
	 	

  
 A-27.

 AMENDMENT AGREEMENT 

THIS AMENDMENT AGREEMENT (this “Amendment”)
is made and entered into as of November 5, 2009, by and among TRIUS THERAPEUTICS, INC., a Delaware corporation (the “Company”) and the parties who are signatories hereto
(the “Existing Holders”). 
 RECITALS 

WHEREAS, the Company and the Existing Holders are parties to an Amended and Restated Investor
Rights Agreement dated as of March 19, 2008 by and among the Company and the Investors listed therein (the “Investor Rights Agreement”); 

WHEREAS, the Company is concurrently herewith consummating a bridge financing transaction pursuant
to a Note Purchase Agreement (the “Purchase Agreement”), under which the Company is issuing secured convertible promissory notes (the “Notes”) on terms and conditions more fully set forth in the
Purchase Agreement; 
 WHEREAS, in connection with the matters set
forth in this Amendment, (i) the provisions of the Investor Rights Agreement may be amended or waived with the written consent of the Company and the holders of at least 66 2/3% of the Registrable Securities (as defined therein) then
outstanding, voting together as a single class on an as-converted basis; 

WHEREAS, the Existing Holders hold the requisite number of shares needed, together with the
Company’s consent, to amend or waive the provisions of the Investor Rights Agreement; and 

WHEREAS, in connection with the transactions contemplated by the Purchase Agreement, the Existing
Holders and the Company desire to amend or waive certain provisions of the Investor Rights Agreement, as more fully set forth herein. 
 AGREEMENT 
 NOW,
THEREFORE, in consideration of the foregoing premises and the mutual covenants and conditions set forth below, and for other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties to this Amendment hereby agree as follows: 
 1. Amendment of Investor Rights
Agreement. The first sentence of Section 1.1(g) of the Investor Rights Agreement shall be amended and restated in its entirety to read as follows: 

“(g) “Registrable Securities” means (a) Common Stock issuable or
issued upon conversion of the Shares, (b) Common Stock issuable or issued upon the conversion of: (i) the notes issued to the Investors pursuant to that certain Note Purchase Agreement by and among the Company and the parties listed as
“Purchasers” thereunder dated November     , 2009 (the “Notes”); or (ii) the Series B Stock issuable or issued upon conversion of the Notes, and (c) any Common Stock issued as
(or 

 
issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of,
such above-described securities.” 
 2. Waiver of Rights of First Refusal. The
undersigned Existing Holders holding greater than 66 2/3% of the Registrable Securities (as such term is defined in the Investor Rights Agreement), for and on behalf of all Investors (as each such term is defined in the Investor Rights Agreement) pursuant to
Sections 4.4 and 5.5 of the Investor Rights Agreement, hereby waive the right to receive notice under Section 4 of the Investor Rights Agreement and waive the right of first refusal set forth in Section 4 of the Investor Rights Agreement
with respect to the Notes issued pursuant to the Purchase Agreement, any shares of Common Stock or Preferred Stock issuable upon conversion of the Notes, and any shares of Common Stock issuable upon conversion of any such shares of Preferred Stock.
 
 3. Miscellaneous. 

(a) Except as specifically amended by this Amendment, the terms and conditions of the Investor Rights Agreement
shall remain in full force and effect. 
 (b) This Amendment may be executed in any number of
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures shall be as effective as original signatures. 

(c) Each party hereto agrees to execute and deliver, or cause to be executed and delivered, such further
instruments or documents or take such other actions as may be reasonably necessary to consummate the transactions contemplated by this Amendment. 
 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 2 

 IN WITNESS
WHEREOF, the parties hereto have executed this AMENDMENT AGREEMENT as of the date first written above. 

 

			
	COMPANY:
	
	TRIUS THERAPEUTICS, INC.
		
	By:	 	 /s/ Jeffrey Stein

		
	Name:	 	 Jeffrey Stein

		
	Title:	 	 President and CEO

  

[SIGNATURE PAGE TO AMENDMENT AGREEMENT] 

 IN WITNESS
WHEREOF, the parties hereto have executed this AMENDMENT AGREEMENT as of the date first written above. 

 

			
	EXISTING HOLDERS:
	
	KPCB HOLDINGS, INC., AS NOMINEE
		
	By:	 	 /s/ Joseph S. Lacob

		
	Name:	 	 Joseph S. Lacob

		
	Title:	 	 Senior Vice President

			
		
	Address:	 	 c/o Kleiner, Perkins, Caufield & Byers
 2750 Sand Hill Road
 Menlo Park, CA 94025

  

[SIGNATURE PAGE TO AMENDMENT AGREEMENT] 

 IN WITNESS
WHEREOF, the parties hereto have executed this AMENDMENT AGREEMENT as of the date first written above. 

 

			
	SOFINNOVA VENTURE PARTNERS VII, L.P.
		
	By:	 	Sofinnova Management VII, L.L.C.
		 	its General Partner
		
	By:	 	 /s/ Michael Powell

		 	Michael Powell
		 	Managing General Partner

			
		
	Address:	 	 140 Geary Street, 10th Floor
 San
Francisco, California 94108

  

[SIGNATURE PAGE TO AMENDMENT AGREEMENT] 

 IN WITNESS
WHEREOF, the parties hereto have executed this AMENDMENT AGREEMENT as of the date first written above. 

 

			
	INTERWEST PARTNERS IX, LP
		
	By:	 	InterWest Management Partners IX, LLC
		 	its General Partner
		
	By:	 	 /s/ Nina Kjellson

		 	Nina Kjellson
		 	Venture Member

			
		
	Address:	 	 2710 Sand Hill Road, Second Floor
 Menlo Park, California 94025

  

[SIGNATURE PAGE TO AMENDMENT AGREEMENT] 

 IN WITNESS
WHEREOF, the parties hereto have executed this AMENDMENT AGREEMENT as of the date first written above. 

 

			
	VERSANT VENTURE CAPITAL III, L.P.
		
	By:	 	Versant Ventures III, LLC
		 	its General Partner
		
	By:	 	 /s/ Brian G. Atwood

		
	Name:	 	 Brian G. Atwood

		
	Title:	 	 Managing Director

			
		
	Address:	 	 3000 Sand Hill Road

Building 4, Suite 210
 Menlo Park, California
94025

			
	
	VERSANT SIDE FUND III, L.P.
		
	By:	 	Versant Ventures III, LLC
		 	its General Partner
		
	By:	 	 /s/ Brian G. Atwood

		
	Name:	 	 Brian G. Atwood

		
	Title:	 	 Managing Director

			
		
	Address:	 	 3000 Sand Hill Road

Building 4, Suite 210
 Menlo Park, California
94025

  

[SIGNATURE PAGE TO AMENDMENT AGREEMENT] 

 IN WITNESS
WHEREOF, the parties hereto have executed this AMENDMENT AGREEMENT as of the date first written above. 

 

			
	PRISM VENTURE PARTNERS V, L.P.
		
	By:	 	Prism Investment Partners V, L.P.
		 	its General Partner
		
	By:	 	Prism Venture Partners V, L.L.C. its General Partner
		
	By:	 	 /s/ Brendan O’Leary

		 	Managing Director

			
		
	Address:	 	 117 Kendrick Street, Suite 200
 Needham, MA 02494

			
	
	PRISM VENTURE PARTNERS V-A, L.P.
		
	By:	 	Prism Investment Partners V, L.P.
		 	its General Partner
		
	By:	 	Prism Venture Partners V, L.L.C.
		 	its General Partner
		
	By:	 	 /s/ Brendan O’Leary

		 	Managing Director

			
		
	Address:	 	 117 Kendrick Street, Suite 200
 Needham, MA 02494

  

[SIGNATURE PAGE TO AMENDMENT AGREEMENT] 

 IN WITNESS
WHEREOF, the parties hereto have executed this AMENDMENT AGREEMENT as of the date first written above. 

 

			
	FINTECH GIMV FUND LP
		
	By:	 	FGF (GP) Management Limited
	Its:	 	General Partner
		
	By:	 	 /s/ Denzil Boschat

		 	Denzil Boschat
		 	Director

			
		
	Address:	 	 La Motte Chambers,
 St
Helier
 Jersey
 Channel
Islands
 JE1 1BJ

  

[SIGNATURE PAGE TO AMENDMENT AGREEMENT] 

 CONVERSION AND AMENDMENT AGREEMENT 

THIS CONVERSION AND AMENDMENT
AGREEMENT (this “Agreement”) is made and entered into as of July 19, 2010, by and among TRIUS THERAPEUTICS, INC., a Delaware
corporation (the “Company”), and the undersigned stockholders of the Company (the “Stockholders”). 
 RECITALS 

WHEREAS, the Company is contemplating the consummation of a firm commitment
underwritten initial public offering of its common stock (the “IPO”); 

WHEREAS, the Stockholders are holders of shares of the Company’s outstanding Series A-1
Preferred Stock (the “Series A-1 Preferred”), Series A-2 Preferred Stock (the “Series A-2 Preferred”), and Series B Preferred Stock (the “Series B Preferred”, together with the
Series A-1 Preferred and the Series A-2 Preferred, the “Series Preferred”), and/or shares of the Company’s Common Stock (“Common Stock”); 

WHEREAS, pursuant to the Company’s Amended and Restated
Certificate of Incorporation, as amended and as may be amended from time to time (the “Restated Certificate”), each share of Series Preferred shall automatically be converted into shares of Common Stock, based on the
then-effective Series Preferred Conversion Price (as defined in the Restated Certificate) applicable to such share of Series Preferred, upon the earlier of (A) the date specified by the affirmative election of the holders of at least 66 2/3% of the outstanding shares of the Series Preferred,
voting together as a single class on an as-if-converted basis, or (B) immediately prior to the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended,
covering the offer and sale of Common Stock for the account of the Company in which (i) the per share price to the public (before underwriting discounts, commissions and fees) is at least $2.00 (as adjusted for stock splits, dividends,
recapitalizations and the like after the filing date hereof), and (ii) the net cash proceeds to the Company (after underwriting discounts, commissions and fees) are at least $30,000,000 (a “Qualified Public Offering”);

 WHEREAS, the Stockholders constitute the holders of at least
66 2/3% of the outstanding shares of the Series
Preferred, voting together as a single class on an as-if-converted basis; 

WHEREAS, the Company and certain of the undersigned Stockholders, among others, are parties to that
certain Amended and Restated Investor Rights Agreement dated as of March 19, 2008, as amended by that certain Amendment Agreement dated as of November 5, 2009 (the “Investor Rights Agreement”), that certain Amended
and Restated Voting Agreement dated as of March 19, 2008 (the “Voting Agreement”), and that certain Amended and Restated Right of First Refusal and Co-Sale Agreement dated as of March 19, 2008 (the
“Co-Sale Agreement”); 
 WHEREAS, the Company and certain of the
undersigned Stockholders, among others, are parties to the Investor Rights Agreement, which contains certain provisions the termination of which is triggered by the closing of a Qualified Public Offering; 

 WHEREAS, the Company and certain of the undersigned
Stockholders, among others, are parties to the Voting Agreement, which terminates in its entirety upon the date of the closing of a Qualified Public Offering; 
 WHEREAS, the Company and certain of the undersigned Stockholders, among others, are parties to the Co-Sale Agreement, which terminates upon the date of the closing of a firm
commitment underwritten public offering by the Company of shares of its Common Stock in connection with which all of the outstanding shares of Series Preferred are converted into shares of Common Stock, pursuant to the Company’s Amended and
Restated Certificate of Incorporation as then in effect; 
 WHEREAS,
the Investor Rights Agreement may be amended or modified, and the obligations of the Company and the rights of the Holders (as defined in the Investor Right Agreement) under the Investor Rights Agreement may be waived, upon the written consent of
the Company and the holders of at least 66 2/3% of
the Registrable Securities (as defined in the Investor Rights Agreement) then outstanding, voting together as a single class on an as-converted basis; 

WHEREAS, the Voting Agreement may be amended or modified, or provisions of the
Voting Agreement waived, upon the written consent of (i) the Company, (ii) holders of at least
66 2/3% of the Series Preferred, voting together as
a single class on an as-if-converted basis, and (iii) holders of a majority of the Key Holder Shares (as defined in the Voting Agreement) held by Key Holders (as defined in the Voting Agreement) then providing services to the Company as an
officer, employee or consultant; 
 WHEREAS, the undersigned stockholders have the
requisite percentages of the applicable securities required to amend the provisions of the Investor Rights Agreement and the Voting Agreement, respectively, and waive certain rights of the Holders under the Investor Rights Agreement as provided
herein; 
 WHEREAS, the undersigned Stockholders desire to assist the Company in
proceeding with an IPO and, in connection therewith, desire to amend certain provisions of the Investor Rights Agreement and the Voting Agreement, respectively, waive certain rights of the Holders under the Investor Rights Agreement, and to confirm
the termination of the Co-Sale Agreement; and 
 WHEREAS, in order to eliminate any
uncertainty or delay with respect to the conversion of the Series Preferred in connection with the IPO the undersigned Stockholders desire to: (i) approve the conversion, effective immediately prior to the closing of the IPO, of each share of
Series Preferred then outstanding into Common Stock at the then-effective applicable Conversion Price, provided that the price per share of the Common Stock sold in the IPO to the public is approved by the Board of Directors of the Company (the
“Board”) or the Pricing Committee of the Board (an “Approved IPO”), and (ii) amend certain provisions of the Investor Rights Agreement and the Voting Agreement, waive certain rights of the Holders
under the Investor Rights Agreement, and confirm the termination of the Co-Sale Agreement, all as more fully set forth herein. 

  
 2. 

 AGREEMENT 

NOW, THEREFORE, the parties to this Agreement, for good and valuable
consideration, the receipt and sufficiency of which are acknowledged and agreed, hereby agree as follows: 
 1. CONVERSION. The Stockholders, holding at least 66 2/3% of the outstanding shares of the Series Preferred, voting together as a single class on an as-if-converted basis, with respect to all shares of Series Preferred held thereby,
hereby agree and provide their written consent that, effective immediately prior to the closing of an Approved IPO, whether or not such Approved IPO constitutes a Qualified Public Offering, all outstanding shares of the Series Preferred shall
automatically be converted into shares of Common Stock at the applicable Conversion Price (each as defined in the Restated Certificate), then in effect. 
 2. AMENDMENT OF INVESTOR RIGHTS AGREEMENT. The Company and the undersigned Stockholders that are holders of Registrable
Securities, with respect to all shares of Registrable Securities held thereby, on behalf of themselves and all other holders of Registrable Securities, hereby amend the Investor Rights Agreement as follows: 

(a) The following defined term in Section 1.1 of the Investor Rights Agreement is hereby amended in its
entirety as follows: 
  “Qualified Public Offering” means an Approved IPO (as defined in that
certain Conversion and Amendment Agreement dated July 19, 2010, by and among the Company and certain stockholders of the Company). 
 (b) Section 4.4(i) of the Investor Rights Agreement is hereby amended to read in its entirety as follows: 
 “the effective date of the registration statement pertaining to a Qualified Public Offering,” 
 3. WAIVER OF REGISTRATION RIGHTS OF INVESTOR RIGHTS AGREEMENT. The Company
and the undersigned Stockholders that are holders of Registrable Securities, with respect to all shares of Registrable Securities held thereby, on behalf of themselves and all other holders of Registrable Securities, hereby waive all registration
rights (including without limitation all rights to notice) under Section 2 of the Investor Rights Agreement with respect to the filing of the registration statement for the IPO and the registration and issuance of the shares in connection with
the IPO. 
 4. AMENDMENT OF VOTING AGREEMENT.
The Company and the undersigned Stockholders, with respect to all shares of Series Preferred and Key Holder Shares held thereby, on behalf of themselves and all other holders of Series Preferred and Key Holder Shares, hereby amend
Section 2.1(a) of the Voting Agreement to read in its entirety as follows: 
 “the date of the closing of an Approved
IPO (as defined in that certain Conversion and Amendment Agreement dated July 19, 2010, by and among the Company and certain stockholders of the Company).” 

  
 3. 

 5. TERMINATION OF
CO-SALE AGREEMENT. The Company and the undersigned Stockholders, on behalf of themselves and all other parties to the Co-Sale Agreement, hereby acknowledge that, effective immediately prior to the
closing of an Approved IPO, the Co-Sale Agreement shall terminate in its entirety and be of no further force or effect pursuant to its terms. 
 6. SUNSET. Notwithstanding anything to the contrary set forth herein, this Agreement and all obligations hereunder shall terminate at 5:00 p.m. Pacific Time on December 31,
2010, if the closing of an Approved IPO has not occurred as of such time. 
 7.
MISCELLANEOUS. 
 (a) Entire Agreement; Binding Effect. This Agreement constitutes the
entire agreement of the parties hereto related to the matters set forth in Sections 1, 2, 3, 4, 5 and 6 hereof, and supersedes all prior agreements between such parties, whether written or oral, related to such subject matter. The terms and
conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties hereto. 
 (b) Amendment; Waiver. Neither this Agreement nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument signed by the Company and each party against
whom enforcement of such amendment, waiver, discharge or termination is sought. 
 (c) Governing Law.
This Agreement shall be governed by and construed in accordance with the laws of the State of California as applied to contracts among California residents entered into and performed entirely within California. 

(d) Counterparts; Facsimile. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures shall be as effective as original signatures. 
 (e) Further Assurances. Each party hereto agrees to execute and deliver, or cause to be executed and delivered, such further instruments or documents or take such other actions as may be reasonably
necessary to consummate the transactions contemplated by this Agreement. 

  
 4. 

 IN WITNESS
WHEREOF, the parties hereto have executed this CONVERSION AND AMENDMENT AGREEMENT as of the date first written above. 

 

			
	 COMPANY:

	
	 TRIUS THERAPEUTICS, INC.

		
	 By:
	 	 /s/ Jeffrey Stein

		 	 Jeffrey Stein, Ph.D.

		 	 President and Chief Executive Officer

 [SIGNATURE PAGE TO CONVERSION AND AMENDMENT AGREEMENT] 

 IN WITNESS WHEREOF, the
parties hereto have executed this CONVERSION AND AMENDMENT AGREEMENT as of the date first written above. 

 

			
	 STOCKHOLDERS:

	
	 KPCB HOLDINGS, INC., AS NOMINEE

		
	 By:
	 	 /s/ Brook Byers

		
	 Name:
	 	 Brook Byers

		
	 Title:
	 	 Senior Vice
President

  

			
	 Address:
	 	 c/o Kleiner, Perkins, Caufield & Byers

		 	 2750 Sand Hill Road

		 	 Menlo Park, CA 94025

 [SIGNATURE PAGE TO CONVERSION AND AMENDMENT AGREEMENT] 

 IN WITNESS
WHEREOF, the parties hereto have executed this CONVERSION AND AMENDMENT AGREEMENT as of the date first written above. 

 

			
	 SOFINNOVA VENTURE PARTNERS VII,
L.P.

		
	 By:
	 	 Sofinnova Management VII, L.L.C.

		 	 its General Partner

		
	 By:
	 	 /s/ Michael Powell

		 	 Michael Powell

		 	 Managing General Partner

 

			
	 Address:
	 	 140 Geary Street,
10th Floor

		 	 San Francisco, California 94108

 [SIGNATURE PAGE TO CONVERSION AND AMENDMENT AGREEMENT] 

 IN WITNESS
WHEREOF, the parties hereto have executed this CONVERSION AND AMENDMENT AGREEMENT as of the date first written above. 

 

			
	 INTERWEST PARTNERS IX, LP

		
	 By:
	 	 InterWest Management Partners IX, LLC
 its General Partner

		
	 By:
	 	 /s/ Nina Kjellson

		 	 Nina Kjellson

		 	 Venture Member

			
		
	 Address:
	 	 2710 Sand Hill Road, Second Floor

		 	 Menlo Park, California 94025

 [SIGNATURE PAGE TO CONVERSION AND AMENDMENT AGREEMENT] 

  

 IN WITNESS
WHEREOF, the parties hereto have executed this CONVERSION AND AMENDMENT AGREEMENT as of the date first written above. 

 

			
	 VERSANT VENTURE CAPITAL III, L.P.

		
	By:	 	Versant Ventures III, LLC
		 	its General Partner
		
	By:	 	 /s/ Brian Atwood

		
	Name:	 	 Brian Atwood

		
	Title:	 	 Managing
Director

			
		
	Address:	 	3000 Sand Hill Road
		 	Building 4, Suite 210
		 	Menlo Park, California 94025
	
	 VERSANT SIDE FUND III,
L.P.

			
		
	By:	 	 Versant Ventures III, LLC

its General Partner

		
	By:	 	 /s/ Brian Atwood

		
	Name:	 	 Brian Atwood

		
	Title:	 	 Managing
Director

			
		
	Address:	 	3000 Sand Hill Road
		 	Building 4, Suite 210
		 	Menlo Park, California 94025

[SIGNATURE PAGE TO CONVERSION AND AMENDMENT
AGREEMENT] 

  

 IN WITNESS
WHEREOF, the parties hereto have executed this CONVERSION AND AMENDMENT AGREEMENT as of the date first written above. 

 

			
	 PRISM VENTURE PARTNERS V, L.P.

		
	 By:
	 	 Prism Investment Partners V, L.P.

		 	 its General Partner

		
	 By:
	 	 Prism Venture Partners V, L.L.C.

		 	 its General Partner

		
	 By:
	 	 /s/ Brendan O’Leary

		 	 Managing Director

 

			
	 Address:
	 	 117 Kendrick Street, Suite 200

		 	 Needham, MA 02494

 

			
	 PRISM VENTURE PARTNERS V-A, L.P.

		
	 By:
	 	 Prism Investment Partners V, L.P.

		 	 its General Partner

		
	 By:
	 	 Prism Venture Partners V, L.L.C.

		 	 its General Partner

		
	 By:
	 	 /s/ Brendan O’Leary

		 	 Managing Director

 

			
	 Address:
	 	 117 Kendrick Street, Suite 200

		 	 Needham, MA 02494

 [SIGNATURE PAGE TO CONVERSION AND AMENDMENT AGREEMENT] 

 IN WITNESS
WHEREOF, the parties hereto have executed this CONVERSION AND AMENDMENT AGREEMENT as of the date first written above. 

 

			
	 /s/ Jeffrey Stein

	 JEFFREY STEIN, PH.D.

	
	JEFF STEIN AND CATHERINE NAUGHTON REVOCABLE
TRUST
		
	 By:
	 	 /s/ Jeffrey Stein

		
	 Name:
	 	 Jeffery Stein, Ph.D.

		
	 Title:
	 	 Trustee

[SIGNATURE PAGE TO CONVERSION AND AMENDMENT
AGREEMENT] 

 IN WITNESS
WHEREOF, the parties hereto have executed this CONVERSION AND AMENDMENT AGREEMENT as of the date first written above. 

 

	
	 /s/ John Schmid

	 JOHN SCHMID

 [SIGNATURE PAGE TO CONVERSION AND AMENDMENT AGREEMENT] 

 IN WITNESS
WHEREOF, the parties hereto have executed this CONVERSION AND AMENDMENT AGREEMENT as of the date first written above. 

 

			
	 /s/ John Finn

	JOHN FINN
	
	 JOHN AND DEBBIE FINN TRUST,

DECLARATION OF TRUST DATED FEBRUARY 25, 2009

		
	By:	 	 /s/ John Finn

		
	Name:	 	 John Finn

		
	Title:	 	 Trustee

[SIGNATURE PAGE TO CONVERSION AND AMENDMENT
AGREEMENT]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}]]